BindingDB logo
myBDB logout

Patent code US9290488

Compile Data Set for Download or QSAR
Found 165 hits of Enzyme Inhibition Constant Data   
Target/Host
(Institution)		LigandTarget/Host
Links		Ligand
Links		Trg + Lig
Links		Ki
nM		ΔG°
kJ/mole		IC50
nM		Kd
nM		EC50/IC50
nM		koff
s-1		kon
M-1s-1		pHTemp
°C
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220380
PNG
(US9290488, ZA01)
Show SMILES NC1(CN(C1)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O)C(O)=O |r,THB:23:22:14.15.21:17.19.18|
Show InChI InChI=1S/C30H41N5O3/c31-30(29(37)38)17-33(18-30)27-28(36)35(26-11-4-3-10-25(26)32-27)24-15-21-8-5-9-22(16-24)34(21)23-13-19-6-1-2-7-20(12-19)14-23/h3-4,10-11,19-24H,1-2,5-9,12-18,31H2,(H,37,38)/t19-,20+,21-,22+,23-,24+
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 0.220 -55.1n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220382
PNG
(US9290488, ZA03)
Show SMILES CN(C)C1(CN(C1)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O)C(O)=O |r,THB:25:24:16.17.23:19.21.20|
Show InChI InChI=1S/C32H45N5O3/c1-34(2)32(31(39)40)19-35(20-32)29-30(38)37(28-13-6-5-12-27(28)33-29)26-17-23-10-7-11-24(18-26)36(23)25-15-21-8-3-4-9-22(14-21)16-25/h5-6,12-13,21-26H,3-4,7-11,14-20H2,1-2H3,(H,39,40)/t21-,22+,23-,24+,25-,26+
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 0.340 -54.0n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220363
PNG
(US9290488, B20a(i))
Show SMILES CC12C[C@@H]3C[C@H]1C[C@H]2C[C@@H](C3)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@@H]2C(O)=O)c1=O |r,THB:9:11:18.19.17:13.15.14|
Show InChI InChI=1S/C31H40N4O3/c1-31-17-18-11-19(31)13-20(31)14-23(12-18)34-21-5-4-6-22(34)16-24(15-21)35-26-8-3-2-7-25(26)32-28(29(35)36)33-10-9-27(33)30(37)38/h2-3,7-8,18-24,27H,4-6,9-17H2,1H3,(H,37,38)/t18-,19+,20+,21-,22+,23-,24+,27-,31?/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 0.890 -51.7n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220366
PNG
(US9290488, B34a)
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC(CC(O)=O)C2)c1=O |r,THB:8:10:17.18.16:12.14.13|
Show InChI InChI=1S/C31H42N4O3/c1-19-9-20-11-21(10-19)13-25(12-20)34-23-5-4-6-24(34)16-26(15-23)35-28-8-3-2-7-27(28)32-30(31(35)38)33-17-22(18-33)14-29(36)37/h2-3,7-8,19-26H,4-6,9-18H2,1H3,(H,36,37)/t19-,20-,21+,23-,24+,25+,26+
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 1.03 -51.3n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220379
PNG
(US9290488, L29b)
Show SMILES OC(=O)CC1CN(C1)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:26:25:17.18.24:20.22.21|
Show InChI InChI=1S/C31H42N4O3/c36-29(37)15-22-18-33(19-22)30-31(38)35(28-11-4-3-10-27(28)32-30)26-16-23-8-5-9-24(17-26)34(23)25-13-20-6-1-2-7-21(12-20)14-25/h3-4,10-11,20-26H,1-2,5-9,12-19H2,(H,36,37)/t20-,21+,23-,24+,25-,26+
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 1.32 -50.7n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220375
PNG
(US9290488, K2b(ii))
Show SMILES OC(=O)[C@@H]1CCN1c1nc2ccccc2n([C@@H]2C[C@@H]3CC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:24:23:16.17.22:19.20|
Show InChI InChI=1S/C29H38N4O3/c34-28-27(31-12-11-26(31)29(35)36)30-24-7-3-4-8-25(24)33(28)23-16-20-9-10-21(17-23)32(20)22-14-18-5-1-2-6-19(13-18)15-22/h3-4,7-8,18-23,26H,1-2,5-6,9-17H2,(H,35,36)/t18-,19+,20-,21+,22-,23+,26-/m0/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 1.46 -50.4n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220384
PNG
(US9290488, ZA05)
Show SMILES CN(C)[C@@H]1CN([C@@H]1C(O)=O)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:28:27:19.20.26:22.24.23|
Show InChI InChI=1S/C32H45N5O3/c1-34(2)28-19-35(29(28)32(39)40)30-31(38)37(27-13-6-5-12-26(27)33-30)25-17-22-10-7-11-23(18-25)36(22)24-15-20-8-3-4-9-21(14-20)16-24/h5-6,12-13,20-25,28-29H,3-4,7-11,14-19H2,1-2H3,(H,39,40)/t20-,21+,22-,23+,24-,25+,28-,29+/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 1.97 -49.7n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220385
PNG
(US9290488, ZA06)
Show SMILES CN[C@@H]1CN([C@@H]1C(O)=O)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:27:26:18.19.25:21.23.22|
Show InChI InChI=1S/C31H43N5O3/c1-32-26-18-34(28(26)31(38)39)29-30(37)36(27-12-5-4-11-25(27)33-29)24-16-21-9-6-10-22(17-24)35(21)23-14-19-7-2-3-8-20(13-19)15-23/h4-5,11-12,19-24,26,28,32H,2-3,6-10,13-18H2,1H3,(H,38,39)/t19-,20+,21-,22+,23-,24+,26-,28+/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 1.98 -49.7n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220383
PNG
(US9290488, ZA04)
Show SMILES N[C@@H]1CN([C@@H]1C(O)=O)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:26:25:17.18.24:20.22.21|
Show InChI InChI=1S/C30H41N5O3/c31-24-17-33(27(24)30(37)38)28-29(36)35(26-11-4-3-10-25(26)32-28)23-15-20-8-5-9-21(16-23)34(20)22-13-18-6-1-2-7-19(12-18)14-22/h3-4,10-11,18-24,27H,1-2,5-9,12-17,31H2,(H,37,38)/t18-,19+,20-,21+,22-,23+,24-,27+/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 1.98 -49.7n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220362
PNG
(US9290488, B12a)
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC(C2)C(O)=O)c1=O |r,THB:8:10:17.18.16:12.14.13|
Show InChI InChI=1S/C30H40N4O3/c1-18-9-19-11-20(10-18)13-24(12-19)33-22-5-4-6-23(33)15-25(14-22)34-27-8-3-2-7-26(27)31-28(29(34)35)32-16-21(17-32)30(36)37/h2-3,7-8,18-25H,4-6,9-17H2,1H3,(H,36,37)/t18-,19-,20+,22-,23+,24+,25+
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 2.21 -49.4n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220376
PNG
(US9290488, K29b)
Show SMILES OC(=O)CC1CN(C1)c1nc2ccccc2n([C@@H]2C[C@@H]3CC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:25:24:17.18.23:20.21|
Show InChI InChI=1S/C30H40N4O3/c35-28(36)14-21-17-32(18-21)29-30(37)34(27-8-4-3-7-26(27)31-29)25-15-22-9-10-23(16-25)33(22)24-12-19-5-1-2-6-20(11-19)13-24/h3-4,7-8,19-25H,1-2,5-6,9-18H2,(H,35,36)/t19-,20+,22-,23+,24-,25+
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 2.64 -49.0n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220377
PNG
(US9290488, L2b(i))
Show SMILES OC(=O)[C@H]1CCN1c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:25:24:16.17.23:19.21.20|
Show InChI InChI=1S/C30H40N4O3/c35-29-28(32-13-12-27(32)30(36)37)31-25-10-3-4-11-26(25)34(29)24-17-21-8-5-9-22(18-24)33(21)23-15-19-6-1-2-7-20(14-19)16-23/h3-4,10-11,19-24,27H,1-2,5-9,12-18H2,(H,36,37)/t19-,20+,21-,22+,23-,24+,27-/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 3.07 -48.6n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220381
PNG
(US9290488, ZA02)
Show SMILES CC(=O)N[C@@H]1CN([C@@H]1C(O)=O)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:29:28:20.21.27:23.25.24|
Show InChI InChI=1S/C32H43N5O4/c1-19(38)33-27-18-35(29(27)32(40)41)30-31(39)37(28-12-5-4-11-26(28)34-30)25-16-22-9-6-10-23(17-25)36(22)24-14-20-7-2-3-8-21(13-20)15-24/h4-5,11-12,20-25,27,29H,2-3,6-10,13-18H2,1H3,(H,33,38)(H,40,41)/t20-,21+,22-,23+,24-,25+,27-,29+/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 3.14 -48.5n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220386
PNG
(US9290488, ZA07)
Show SMILES CO[C@H]1CN([C@@H]1C(O)=O)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:27:26:18.19.25:21.23.22|
Show InChI InChI=1S/C31H42N4O4/c1-39-27-18-33(28(27)31(37)38)29-30(36)35(26-12-5-4-11-25(26)32-29)24-16-21-9-6-10-22(17-24)34(21)23-14-19-7-2-3-8-20(13-19)15-23/h4-5,11-12,19-24,27-28H,2-3,6-10,13-18H2,1H3,(H,37,38)/t19-,20+,21-,22+,23-,24+,27-,28-/m0/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 3.56 -48.2n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220378
PNG
(US9290488, L2b(ii))
Show SMILES OC(=O)[C@@H]1CCN1c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:25:24:16.17.23:19.21.20|
Show InChI InChI=1S/C30H40N4O3/c35-29-28(32-13-12-27(32)30(36)37)31-25-10-3-4-11-26(25)34(29)24-17-21-8-5-9-22(18-24)33(21)23-15-19-6-1-2-7-20(14-19)16-23/h3-4,10-11,19-24,27H,1-2,5-9,12-18H2,(H,36,37)/t19-,20+,21-,22+,23-,24+,27-/m0/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 3.78 -48.1n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220373
PNG
(US9290488, E54a)
Show SMILES CC1(C)[C@@H]2C[C@H]1[C@H](CCN1[C@H]3CCC[C@@H]1C[C@@H](C3)n1c3ccccc3nc(N3CC(C3)C(O)=O)c1=O)CC2 |r,THB:8:9:16.17.15:11.13.12|
Show InChI InChI=1S/C31H42N4O3/c1-31(2)21-11-10-19(25(31)14-21)12-13-34-22-6-5-7-23(34)16-24(15-22)35-27-9-4-3-8-26(27)32-28(29(35)36)33-17-20(18-33)30(37)38/h3-4,8-9,19-25H,5-7,10-18H2,1-2H3,(H,37,38)/t19-,21-,22-,23+,24+,25-/m0/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 5.46 -47.2n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220384
PNG
(US9290488, ZA05)
Show SMILES CN(C)[C@@H]1CN([C@@H]1C(O)=O)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:28:27:19.20.26:22.24.23|
Show InChI InChI=1S/C32H45N5O3/c1-34(2)28-19-35(29(28)32(39)40)30-31(38)37(27-13-6-5-12-26(27)33-30)25-17-22-10-7-11-23(18-25)36(22)24-15-20-8-3-4-9-21(14-20)16-24/h5-6,12-13,20-25,28-29H,3-4,7-11,14-19H2,1-2H3,(H,39,40)/t20-,21+,22-,23+,24-,25+,28-,29+/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 7.40 -46.4n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 μg membrane protein (recombinant kappa opioid rece...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220364
PNG
(US9290488, B20a(ii))
Show SMILES CC12C[C@@H]3C[C@H]1C[C@H]2C[C@@H](C3)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@H]2C(O)=O)c1=O |r,THB:9:11:18.19.17:13.15.14|
Show InChI InChI=1S/C31H40N4O3/c1-31-17-18-11-19(31)13-20(31)14-23(12-18)34-21-5-4-6-22(34)16-24(15-21)35-26-8-3-2-7-25(26)32-28(29(35)36)33-10-9-27(33)30(37)38/h2-3,7-8,18-24,27H,4-6,9-17H2,1H3,(H,37,38)/t18-,19+,20+,21-,22+,23-,24+,27+,31?/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 7.44 -46.4n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220365
PNG
(US9290488, B21a)
Show SMILES CC12C[C@@H]3C[C@H]1C[C@H]2C[C@@H](C3)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC(C2)C(O)=O)c1=O |r,THB:9:11:18.19.17:13.15.14|
Show InChI InChI=1S/C31H40N4O3/c1-31-15-18-9-20(31)11-21(31)12-24(10-18)34-22-5-4-6-23(34)14-25(13-22)35-27-8-3-2-7-26(27)32-28(29(35)36)33-16-19(17-33)30(37)38/h2-3,7-8,18-25H,4-6,9-17H2,1H3,(H,37,38)/t18-,20+,21+,22-,23+,24-,25+,31?/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 8.22 -46.1n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220360
PNG
(US9290488, B11a(i))
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@@H]2C(O)=O)c1=O |r,THB:8:10:17.18.16:12.14.13|
Show InChI InChI=1S/C30H40N4O3/c1-18-11-19-13-20(12-18)15-23(14-19)33-21-5-4-6-22(33)17-24(16-21)34-26-8-3-2-7-25(26)31-28(29(34)35)32-10-9-27(32)30(36)37/h2-3,7-8,18-24,27H,4-6,9-17H2,1H3,(H,36,37)/t18-,19-,20+,21-,22+,23+,24+,27-/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 9.80 -45.7n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220374
PNG
(US9290488, H3a)
Show SMILES OC(=O)C1CN(C1)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3C2CCCCCCCCC2)c1=O |r,THB:25:24:16.17.23:19.21.20|
Show InChI InChI=1S/C30H42N4O3/c35-29-28(32-19-21(20-32)30(36)37)31-26-15-8-9-16-27(26)34(29)25-17-23-13-10-14-24(18-25)33(23)22-11-6-4-2-1-3-5-7-12-22/h8-9,15-16,21-25H,1-7,10-14,17-20H2,(H,36,37)/t23-,24+,25+
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 9.93 -45.7n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220383
PNG
(US9290488, ZA04)
Show SMILES N[C@@H]1CN([C@@H]1C(O)=O)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:26:25:17.18.24:20.22.21|
Show InChI InChI=1S/C30H41N5O3/c31-24-17-33(27(24)30(37)38)28-29(36)35(26-11-4-3-10-25(26)32-28)23-15-20-8-5-9-21(16-23)34(20)22-13-18-6-1-2-7-19(12-18)14-22/h3-4,10-11,18-24,27H,1-2,5-9,12-17,31H2,(H,37,38)/t18-,19+,20-,21+,22-,23+,24-,27+/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 11.6 -45.3n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 μg membrane protein (recombinant kappa opioid rece...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220387
PNG
(US9290488, ZA08)
Show SMILES CO[C@H]1CN([C@@H]1C(O)=O)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@@H]2C[C@H]3CCC[C@H](C3)C2)c1=O |r,THB:27:26:18.19.25:21.23.22|
Show InChI InChI=1S/C30H40N4O4/c1-38-26-17-32(27(26)30(36)37)28-29(35)34(25-11-3-2-10-24(25)31-28)23-15-20-8-5-9-21(16-23)33(20)22-13-18-6-4-7-19(12-18)14-22/h2-3,10-11,18-23,26-27H,4-9,12-17H2,1H3,(H,36,37)/t18-,19+,20-,21+,22+,23+,26-,27-/m0/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 11.9 -45.2n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220388
PNG
(US9290488, ZA09)
Show SMILES N[C@@H]1CN([C@@H]1C(O)=O)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@@H]2C[C@H]3CCC[C@H](C3)C2)c1=O |r,THB:26:25:17.18.24:20.22.21|
Show InChI InChI=1S/C29H39N5O3/c30-23-16-32(26(23)29(36)37)27-28(35)34(25-10-2-1-9-24(25)31-27)22-14-19-7-4-8-20(15-22)33(19)21-12-17-5-3-6-18(11-17)13-21/h1-2,9-10,17-23,26H,3-8,11-16,30H2,(H,36,37)/t17-,18+,19-,20+,21+,22+,23-,26+/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 11.9 -45.2n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220361
PNG
(US9290488, B11a(ii))
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@H]2C(O)=O)c1=O |r,THB:8:10:17.18.16:12.14.13|
Show InChI InChI=1S/C30H40N4O3/c1-18-11-19-13-20(12-18)15-23(14-19)33-21-5-4-6-22(33)17-24(16-21)34-26-8-3-2-7-25(26)31-28(29(34)35)32-10-9-27(32)30(36)37/h2-3,7-8,18-24,27H,4-6,9-17H2,1H3,(H,36,37)/t18-,19-,20+,21-,22+,23+,24+,27-/m0/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 12.1 -45.2n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220392
PNG
(US9290488, CC02)
Show SMILES CC12C[C@@H]3C[C@H]1C[C@H]2C[C@@H](C3)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CCC[C@H]2C(O)=O)c1=O |r,THB:9:11:18.19.17:13.15.14|
Show InChI InChI=1S/C32H42N4O3/c1-32-18-19-12-20(32)14-21(32)15-24(13-19)35-22-6-4-7-23(35)17-25(16-22)36-27-9-3-2-8-26(27)33-29(30(36)37)34-11-5-10-28(34)31(38)39/h2-3,8-9,19-25,28H,4-7,10-18H2,1H3,(H,38,39)/t19-,20+,21+,22-,23+,24-,25+,28+,32?/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 15 -44.7n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220357
PNG
(US9290488, A11a(ii))
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@H]2C(O)=O)c1=O |r,THB:8:10:16.17.15:12.13|
Show InChI InChI=1S/C29H38N4O3/c1-17-10-18-12-19(11-17)14-22(13-18)32-20-6-7-21(32)16-23(15-20)33-25-5-3-2-4-24(25)30-27(28(33)34)31-9-8-26(31)29(35)36/h2-5,17-23,26H,6-16H2,1H3,(H,35,36)/t17-,18-,19+,20-,21+,22+,23+,26-/m0/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 19.2 -44.0n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220389
PNG
(US9290488, ZA10)
Show SMILES CN(C)[C@@H]1CN([C@@H]1C(O)=O)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@@H]2C[C@H]3CCC[C@H](C3)C2)c1=O |r,THB:28:27:19.20.26:22.24.23|
Show InChI InChI=1S/C31H43N5O3/c1-33(2)27-18-34(28(27)31(38)39)29-30(37)36(26-12-4-3-11-25(26)32-29)24-16-21-9-6-10-22(17-24)35(21)23-14-19-7-5-8-20(13-19)15-23/h3-4,11-12,19-24,27-28H,5-10,13-18H2,1-2H3,(H,38,39)/t19-,20+,21-,22+,23+,24+,27-,28+/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 23 -43.6n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220372
PNG
(US9290488, E53a(ii))
Show SMILES CC1(C)[C@@H]2C[C@H]1[C@H](CCN1[C@H]3CCC[C@@H]1C[C@@H](C3)n1c3ccccc3nc(N3CC[C@H]3C(O)=O)c1=O)CC2 |r,THB:8:9:16.17.15:11.13.12|
Show InChI InChI=1S/C31H42N4O3/c1-31(2)20-11-10-19(24(31)16-20)12-14-33-21-6-5-7-22(33)18-23(17-21)35-26-9-4-3-8-25(26)32-28(29(35)36)34-15-13-27(34)30(37)38/h3-4,8-9,19-24,27H,5-7,10-18H2,1-2H3,(H,37,38)/t19-,20-,21-,22+,23+,24-,27-/m0/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 23.6 -43.5n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220359
PNG
(US9290488, B2a(ii))
Show SMILES OC(=O)[C@@H]1CCN1c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@@H]2C[C@H]3CCC[C@H](C3)C2)c1=O |r,THB:25:24:16.17.23:19.21.20|
Show InChI InChI=1S/C29H38N4O3/c34-28-27(31-12-11-26(31)29(35)36)30-24-9-1-2-10-25(24)33(28)23-16-20-7-4-8-21(17-23)32(20)22-14-18-5-3-6-19(13-18)15-22/h1-2,9-10,18-23,26H,3-8,11-17H2,(H,35,36)/t18-,19+,20-,21+,22+,23+,26-/m0/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 27.1 -43.2n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220362
PNG
(US9290488, B12a)
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC(C2)C(O)=O)c1=O |r,THB:8:10:17.18.16:12.14.13|
Show InChI InChI=1S/C30H40N4O3/c1-18-9-19-11-20(10-18)13-24(12-19)33-22-5-4-6-23(33)15-25(14-22)34-27-8-3-2-7-26(27)31-28(29(34)35)32-16-21(17-32)30(36)37/h2-3,7-8,18-25H,4-6,9-17H2,1H3,(H,36,37)/t18-,19-,20+,22-,23+,24+,25+
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 29.1 -43.0n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220391
PNG
(US9290488, CC01)
Show SMILES OC(=O)[C@@H]1CCCN1c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@@H]2C[C@H]3CCC[C@H](C3)C2)c1=O |r,THB:26:25:17.18.24:20.22.21|
Show InChI InChI=1S/C30H40N4O3/c35-29-28(32-13-5-12-27(32)30(36)37)31-25-10-1-2-11-26(25)34(29)24-17-21-8-4-9-22(18-24)33(21)23-15-19-6-3-7-20(14-19)16-23/h1-2,10-11,19-24,27H,3-9,12-18H2,(H,36,37)/t19-,20+,21-,22+,23+,24+,27-/m0/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 38 -42.4n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 μg membrane protein (recombinant kappa opioid rece...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220363
PNG
(US9290488, B20a(i))
Show SMILES CC12C[C@@H]3C[C@H]1C[C@H]2C[C@@H](C3)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@@H]2C(O)=O)c1=O |r,THB:9:11:18.19.17:13.15.14|
Show InChI InChI=1S/C31H40N4O3/c1-31-17-18-11-19(31)13-20(31)14-23(12-18)34-21-5-4-6-22(34)16-24(15-21)35-26-8-3-2-7-25(26)32-28(29(35)36)33-10-9-27(33)30(37)38/h2-3,7-8,18-24,27H,4-6,9-17H2,1H3,(H,37,38)/t18-,19+,20+,21-,22+,23-,24+,27-,31?/m1/s1
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 38.9 -42.3n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220390
PNG
(US9290488, ZA11)
Show SMILES CC(=O)N[C@@H]1CN([C@@H]1C(O)=O)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@@H]2C[C@H]3CCC[C@H](C3)C2)c1=O |r,THB:29:28:20.21.27:23.25.24|
Show InChI InChI=1S/C31H41N5O4/c1-18(37)32-26-17-34(28(26)31(39)40)29-30(38)36(27-11-3-2-10-25(27)33-29)24-15-21-8-5-9-22(16-24)35(21)23-13-19-6-4-7-20(12-19)14-23/h2-3,10-11,19-24,26,28H,4-9,12-17H2,1H3,(H,32,37)(H,39,40)/t19-,20+,21-,22+,23+,24+,26-,28+/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 39.9 -42.2n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220361
PNG
(US9290488, B11a(ii))
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@H]2C(O)=O)c1=O |r,THB:8:10:17.18.16:12.14.13|
Show InChI InChI=1S/C30H40N4O3/c1-18-11-19-13-20(12-18)15-23(14-19)33-21-5-4-6-22(33)17-24(16-21)34-26-8-3-2-7-25(26)31-28(29(34)35)32-10-9-27(32)30(36)37/h2-3,7-8,18-24,27H,4-6,9-17H2,1H3,(H,36,37)/t18-,19-,20+,21-,22+,23+,24+,27-/m0/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 40.8 -42.2n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 μg membrane protein (recombinant kappa opioid rece...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220356
PNG
(US9290488, A11a(i))
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@@H]2C(O)=O)c1=O |r,THB:8:10:16.17.15:12.13|
Show InChI InChI=1S/C29H38N4O3/c1-17-10-18-12-19(11-17)14-22(13-18)32-20-6-7-21(32)16-23(15-20)33-25-5-3-2-4-24(25)30-27(28(33)34)31-9-8-26(31)29(35)36/h2-5,17-23,26H,6-16H2,1H3,(H,35,36)/t17-,18-,19+,20-,21+,22+,23+,26-/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 43 -42.0n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220366
PNG
(US9290488, B34a)
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC(CC(O)=O)C2)c1=O |r,THB:8:10:17.18.16:12.14.13|
Show InChI InChI=1S/C31H42N4O3/c1-19-9-20-11-21(10-19)13-25(12-20)34-23-5-4-6-24(34)16-26(15-23)35-28-8-3-2-7-27(28)32-30(31(35)38)33-17-22(18-33)14-29(36)37/h2-3,7-8,19-26H,4-6,9-18H2,1H3,(H,36,37)/t19-,20-,21+,23-,24+,25+,26+
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 43.4 -42.0n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220361
PNG
(US9290488, B11a(ii))
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@H]2C(O)=O)c1=O |r,THB:8:10:17.18.16:12.14.13|
Show InChI InChI=1S/C30H40N4O3/c1-18-11-19-13-20(12-18)15-23(14-19)33-21-5-4-6-22(33)17-24(16-21)34-26-8-3-2-7-25(26)31-28(29(34)35)32-10-9-27(32)30(36)37/h2-3,7-8,18-24,27H,4-6,9-17H2,1H3,(H,36,37)/t18-,19-,20+,21-,22+,23+,24+,27-/m0/s1
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 48.9 -41.7n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220392
PNG
(US9290488, CC02)
Show SMILES CC12C[C@@H]3C[C@H]1C[C@H]2C[C@@H](C3)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CCC[C@H]2C(O)=O)c1=O |r,THB:9:11:18.19.17:13.15.14|
Show InChI InChI=1S/C32H42N4O3/c1-32-18-19-12-20(32)14-21(32)15-24(13-19)35-22-6-4-7-23(35)17-25(16-22)36-27-9-3-2-8-26(27)33-29(30(36)37)34-11-5-10-28(34)31(38)39/h2-3,8-9,19-25,28H,4-7,10-18H2,1H3,(H,38,39)/t19-,20+,21+,22-,23+,24-,25+,28+,32?/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 51 -41.6n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 μg membrane protein (recombinant kappa opioid rece...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220365
PNG
(US9290488, B21a)
Show SMILES CC12C[C@@H]3C[C@H]1C[C@H]2C[C@@H](C3)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC(C2)C(O)=O)c1=O |r,THB:9:11:18.19.17:13.15.14|
Show InChI InChI=1S/C31H40N4O3/c1-31-15-18-9-20(31)11-21(31)12-24(10-18)34-22-5-4-6-23(34)14-25(13-22)35-27-8-3-2-7-26(27)32-28(29(35)36)33-16-19(17-33)30(37)38/h2-3,7-8,18-25H,4-6,9-17H2,1H3,(H,37,38)/t18-,20+,21+,22-,23+,24-,25+,31?/m1/s1
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 54.1 -41.5n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220368
PNG
(US9290488, C20a(ii))
Show SMILES CC12C[C@@H]3C[C@H]1C[C@H]2C[C@@H](C3)N1[C@H]2COC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@H]2C(O)=O)c1=O |r,THB:9:11:18.19.17:13.15.14|
Show InChI InChI=1S/C30H38N4O4/c1-30-14-17-8-18(30)10-19(30)11-20(9-17)33-22-12-21(13-23(33)16-38-15-22)34-25-5-3-2-4-24(25)31-27(28(34)35)32-7-6-26(32)29(36)37/h2-5,17-23,26H,6-16H2,1H3,(H,36,37)/t17-,18+,19+,20-,21-,22-,23+,26+,30?/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 55.5 -41.4n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220384
PNG
(US9290488, ZA05)
Show SMILES CN(C)[C@@H]1CN([C@@H]1C(O)=O)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:28:27:19.20.26:22.24.23|
Show InChI InChI=1S/C32H45N5O3/c1-34(2)28-19-35(29(28)32(39)40)30-31(38)37(27-13-6-5-12-26(27)33-30)25-17-22-10-7-11-23(18-25)36(22)24-15-20-8-3-4-9-21(14-20)16-24/h5-6,12-13,20-25,28-29H,3-4,7-11,14-19H2,1-2H3,(H,39,40)/t20-,21+,22-,23+,24-,25+,28-,29+/m1/s1
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 57 -41.3n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220366
PNG
(US9290488, B34a)
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC(CC(O)=O)C2)c1=O |r,THB:8:10:17.18.16:12.14.13|
Show InChI InChI=1S/C31H42N4O3/c1-19-9-20-11-21(10-19)13-25(12-20)34-23-5-4-6-24(34)16-26(15-23)35-28-8-3-2-7-27(28)32-30(31(35)38)33-17-22(18-33)14-29(36)37/h2-3,7-8,19-26H,4-6,9-18H2,1H3,(H,36,37)/t19-,20-,21+,23-,24+,25+,26+
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 72.3 -40.8n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 μg membrane protein (recombinant kappa opioid rece...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220371
PNG
(US9290488, E53a(i))
Show SMILES CC1(C)[C@@H]2C[C@H]1[C@H](CCN1[C@H]3CCC[C@@H]1C[C@@H](C3)n1c3ccccc3nc(N3CC[C@@H]3C(O)=O)c1=O)CC2 |r,THB:8:9:16.17.15:11.13.12|
Show InChI InChI=1S/C31H42N4O3/c1-31(2)20-11-10-19(24(31)16-20)12-14-33-21-6-5-7-22(33)18-23(17-21)35-26-9-4-3-8-25(26)32-28(29(35)36)34-15-13-27(34)30(37)38/h3-4,8-9,19-24,27H,5-7,10-18H2,1-2H3,(H,37,38)/t19-,20-,21-,22+,23+,24-,27+/m0/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 80 -40.5n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220383
PNG
(US9290488, ZA04)
Show SMILES N[C@@H]1CN([C@@H]1C(O)=O)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:26:25:17.18.24:20.22.21|
Show InChI InChI=1S/C30H41N5O3/c31-24-17-33(27(24)30(37)38)28-29(36)35(26-11-4-3-10-25(26)32-28)23-15-20-8-5-9-21(16-23)34(20)22-13-18-6-1-2-7-19(12-18)14-22/h3-4,10-11,18-24,27H,1-2,5-9,12-17,31H2,(H,37,38)/t18-,19+,20-,21+,22-,23+,24-,27+/m1/s1
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 83 -40.4n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220392
PNG
(US9290488, CC02)
Show SMILES CC12C[C@@H]3C[C@H]1C[C@H]2C[C@@H](C3)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CCC[C@H]2C(O)=O)c1=O |r,THB:9:11:18.19.17:13.15.14|
Show InChI InChI=1S/C32H42N4O3/c1-32-18-19-12-20(32)14-21(32)15-24(13-19)35-22-6-4-7-23(35)17-25(16-22)36-27-9-3-2-8-26(27)33-29(30(36)37)34-11-5-10-28(34)31(38)39/h2-3,8-9,19-25,28H,4-7,10-18H2,1H3,(H,38,39)/t19-,20+,21+,22-,23+,24-,25+,28+,32?/m1/s1
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 86 -40.3n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220378
PNG
(US9290488, L2b(ii))
Show SMILES OC(=O)[C@@H]1CCN1c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:25:24:16.17.23:19.21.20|
Show InChI InChI=1S/C30H40N4O3/c35-29-28(32-13-12-27(32)30(36)37)31-25-10-3-4-11-26(25)34(29)24-17-21-8-5-9-22(18-24)33(21)23-15-19-6-1-2-7-20(14-19)16-23/h3-4,10-11,19-24,27H,1-2,5-9,12-18H2,(H,36,37)/t19-,20+,21-,22+,23-,24+,27-/m0/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 86 -40.3n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 μg membrane protein (recombinant kappa opioid rece...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220358
PNG
(US9290488, B2a(i))
Show SMILES OC(=O)[C@H]1CCN1c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@@H]2C[C@H]3CCC[C@H](C3)C2)c1=O |r,THB:25:24:16.17.23:19.21.20|
Show InChI InChI=1S/C29H38N4O3/c34-28-27(31-12-11-26(31)29(35)36)30-24-9-1-2-10-25(24)33(28)23-16-20-7-4-8-21(17-23)32(20)22-14-18-5-3-6-19(13-18)15-22/h1-2,9-10,18-23,26H,3-8,11-17H2,(H,35,36)/t18-,19+,20-,21+,22+,23+,26-/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 93.5 -40.1n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220391
PNG
(US9290488, CC01)
Show SMILES OC(=O)[C@@H]1CCCN1c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@@H]2C[C@H]3CCC[C@H](C3)C2)c1=O |r,THB:26:25:17.18.24:20.22.21|
Show InChI InChI=1S/C30H40N4O3/c35-29-28(32-13-5-12-27(32)30(36)37)31-25-10-1-2-11-26(25)34(29)24-17-21-8-4-9-22(18-24)33(21)23-15-19-6-3-7-20(14-19)16-23/h1-2,10-11,19-24,27H,3-9,12-18H2,(H,36,37)/t19-,20+,21-,22+,23+,24+,27-/m0/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 98 -40.0n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220365
PNG
(US9290488, B21a)
Show SMILES CC12C[C@@H]3C[C@H]1C[C@H]2C[C@@H](C3)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC(C2)C(O)=O)c1=O |r,THB:9:11:18.19.17:13.15.14|
Show InChI InChI=1S/C31H40N4O3/c1-31-15-18-9-20(31)11-21(31)12-24(10-18)34-22-5-4-6-23(34)14-25(13-22)35-27-8-3-2-7-26(27)32-28(29(35)36)33-16-19(17-33)30(37)38/h2-3,7-8,18-25H,4-6,9-17H2,1H3,(H,37,38)/t18-,20+,21+,22-,23+,24-,25+,31?/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 111 -39.7n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 μg membrane protein (recombinant kappa opioid rece...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220362
PNG
(US9290488, B12a)
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC(C2)C(O)=O)c1=O |r,THB:8:10:17.18.16:12.14.13|
Show InChI InChI=1S/C30H40N4O3/c1-18-9-19-11-20(10-18)13-24(12-19)33-22-5-4-6-23(33)15-25(14-22)34-27-8-3-2-7-26(27)31-28(29(34)35)32-16-21(17-32)30(36)37/h2-3,7-8,18-25H,4-6,9-17H2,1H3,(H,36,37)/t18-,19-,20+,22-,23+,24+,25+
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 113 -39.7n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 μg membrane protein (recombinant kappa opioid rece...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220357
PNG
(US9290488, A11a(ii))
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@H]2C(O)=O)c1=O |r,THB:8:10:16.17.15:12.13|
Show InChI InChI=1S/C29H38N4O3/c1-17-10-18-12-19(11-17)14-22(13-18)32-20-6-7-21(32)16-23(15-20)33-25-5-3-2-4-24(25)30-27(28(33)34)31-9-8-26(31)29(35)36/h2-5,17-23,26H,6-16H2,1H3,(H,35,36)/t17-,18-,19+,20-,21+,22+,23+,26-/m0/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 116 -39.6n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 μg membrane protein (recombinant kappa opioid rece...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220378
PNG
(US9290488, L2b(ii))
Show SMILES OC(=O)[C@@H]1CCN1c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:25:24:16.17.23:19.21.20|
Show InChI InChI=1S/C30H40N4O3/c35-29-28(32-13-12-27(32)30(36)37)31-25-10-3-4-11-26(25)34(29)24-17-21-8-5-9-22(18-24)33(21)23-15-19-6-1-2-7-20(14-19)16-23/h3-4,10-11,19-24,27H,1-2,5-9,12-18H2,(H,36,37)/t19-,20+,21-,22+,23-,24+,27-/m0/s1
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 128 -39.3n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220371
PNG
(US9290488, E53a(i))
Show SMILES CC1(C)[C@@H]2C[C@H]1[C@H](CCN1[C@H]3CCC[C@@H]1C[C@@H](C3)n1c3ccccc3nc(N3CC[C@@H]3C(O)=O)c1=O)CC2 |r,THB:8:9:16.17.15:11.13.12|
Show InChI InChI=1S/C31H42N4O3/c1-31(2)20-11-10-19(24(31)16-20)12-14-33-21-6-5-7-22(33)18-23(17-21)35-26-9-4-3-8-25(26)32-28(29(35)36)34-15-13-27(34)30(37)38/h3-4,8-9,19-24,27H,5-7,10-18H2,1-2H3,(H,37,38)/t19-,20-,21-,22+,23+,24-,27+/m0/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 128 -39.3n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 μg membrane protein (recombinant kappa opioid rece...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220376
PNG
(US9290488, K29b)
Show SMILES OC(=O)CC1CN(C1)c1nc2ccccc2n([C@@H]2C[C@@H]3CC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:25:24:17.18.23:20.21|
Show InChI InChI=1S/C30H40N4O3/c35-28(36)14-21-17-32(18-21)29-30(37)34(27-8-4-3-7-26(27)31-29)25-15-22-9-10-23(16-25)33(22)24-12-19-5-1-2-6-20(11-19)13-24/h3-4,7-8,19-25H,1-2,5-6,9-18H2,(H,35,36)/t19-,20+,22-,23+,24-,25+
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 135 -39.2n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 μg membrane protein (recombinant kappa opioid rece...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220377
PNG
(US9290488, L2b(i))
Show SMILES OC(=O)[C@H]1CCN1c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:25:24:16.17.23:19.21.20|
Show InChI InChI=1S/C30H40N4O3/c35-29-28(32-13-12-27(32)30(36)37)31-25-10-3-4-11-26(25)34(29)24-17-21-8-5-9-22(18-24)33(21)23-15-19-6-1-2-7-20(14-19)16-23/h3-4,10-11,19-24,27H,1-2,5-9,12-18H2,(H,36,37)/t19-,20+,21-,22+,23-,24+,27-/m1/s1
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 136 -39.2n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220363
PNG
(US9290488, B20a(i))
Show SMILES CC12C[C@@H]3C[C@H]1C[C@H]2C[C@@H](C3)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@@H]2C(O)=O)c1=O |r,THB:9:11:18.19.17:13.15.14|
Show InChI InChI=1S/C31H40N4O3/c1-31-17-18-11-19(31)13-20(31)14-23(12-18)34-21-5-4-6-22(34)16-24(15-21)35-26-8-3-2-7-25(26)32-28(29(35)36)33-10-9-27(33)30(37)38/h2-3,7-8,18-24,27H,4-6,9-17H2,1H3,(H,37,38)/t18-,19+,20+,21-,22+,23-,24+,27-,31?/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 137 -39.2n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 μg membrane protein (recombinant kappa opioid rece...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220364
PNG
(US9290488, B20a(ii))
Show SMILES CC12C[C@@H]3C[C@H]1C[C@H]2C[C@@H](C3)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@H]2C(O)=O)c1=O |r,THB:9:11:18.19.17:13.15.14|
Show InChI InChI=1S/C31H40N4O3/c1-31-17-18-11-19(31)13-20(31)14-23(12-18)34-21-5-4-6-22(34)16-24(15-21)35-26-8-3-2-7-25(26)32-28(29(35)36)33-10-9-27(33)30(37)38/h2-3,7-8,18-24,27H,4-6,9-17H2,1H3,(H,37,38)/t18-,19+,20+,21-,22+,23-,24+,27+,31?/m1/s1
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 154 -38.9n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220364
PNG
(US9290488, B20a(ii))
Show SMILES CC12C[C@@H]3C[C@H]1C[C@H]2C[C@@H](C3)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@H]2C(O)=O)c1=O |r,THB:9:11:18.19.17:13.15.14|
Show InChI InChI=1S/C31H40N4O3/c1-31-17-18-11-19(31)13-20(31)14-23(12-18)34-21-5-4-6-22(34)16-24(15-21)35-26-8-3-2-7-25(26)32-28(29(35)36)33-10-9-27(33)30(37)38/h2-3,7-8,18-24,27H,4-6,9-17H2,1H3,(H,37,38)/t18-,19+,20+,21-,22+,23-,24+,27+,31?/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 159 -38.8n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 μg membrane protein (recombinant kappa opioid rece...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220377
PNG
(US9290488, L2b(i))
Show SMILES OC(=O)[C@H]1CCN1c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:25:24:16.17.23:19.21.20|
Show InChI InChI=1S/C30H40N4O3/c35-29-28(32-13-12-27(32)30(36)37)31-25-10-3-4-11-26(25)34(29)24-17-21-8-5-9-22(18-24)33(21)23-15-19-6-1-2-7-20(14-19)16-23/h3-4,10-11,19-24,27H,1-2,5-9,12-18H2,(H,36,37)/t19-,20+,21-,22+,23-,24+,27-/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 188 -38.4n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 μg membrane protein (recombinant kappa opioid rece...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220357
PNG
(US9290488, A11a(ii))
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@H]2C(O)=O)c1=O |r,THB:8:10:16.17.15:12.13|
Show InChI InChI=1S/C29H38N4O3/c1-17-10-18-12-19(11-17)14-22(13-18)32-20-6-7-21(32)16-23(15-20)33-25-5-3-2-4-24(25)30-27(28(33)34)31-9-8-26(31)29(35)36/h2-5,17-23,26H,6-16H2,1H3,(H,35,36)/t17-,18-,19+,20-,21+,22+,23+,26-/m0/s1
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 219 -38.0n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220375
PNG
(US9290488, K2b(ii))
Show SMILES OC(=O)[C@@H]1CCN1c1nc2ccccc2n([C@@H]2C[C@@H]3CC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:24:23:16.17.22:19.20|
Show InChI InChI=1S/C29H38N4O3/c34-28-27(31-12-11-26(31)29(35)36)30-24-7-3-4-8-25(24)33(28)23-16-20-9-10-21(17-23)32(20)22-14-18-5-1-2-6-19(13-18)15-22/h3-4,7-8,18-23,26H,1-2,5-6,9-17H2,(H,35,36)/t18-,19+,20-,21+,22-,23+,26-/m0/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 223 -38.0n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 μg membrane protein (recombinant kappa opioid rece...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220375
PNG
(US9290488, K2b(ii))
Show SMILES OC(=O)[C@@H]1CCN1c1nc2ccccc2n([C@@H]2C[C@@H]3CC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:24:23:16.17.22:19.20|
Show InChI InChI=1S/C29H38N4O3/c34-28-27(31-12-11-26(31)29(35)36)30-24-7-3-4-8-25(24)33(28)23-16-20-9-10-21(17-23)32(20)22-14-18-5-1-2-6-19(13-18)15-22/h3-4,7-8,18-23,26H,1-2,5-6,9-17H2,(H,35,36)/t18-,19+,20-,21+,22-,23+,26-/m0/s1
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 259 -37.6n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220370
PNG
(US9290488, C39a)
Show SMILES CC12C[C@@H]3C[C@H]1C[C@H]2C[C@@H](C3)N1[C@H]2COC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC(CC(O)=O)C2)c1=O |r,THB:9:11:18.19.17:13.15.14|
Show InChI InChI=1S/C31H40N4O4/c1-31-13-18-6-20(31)9-21(31)10-22(7-18)34-24-11-23(12-25(34)17-39-16-24)35-27-5-3-2-4-26(27)32-29(30(35)38)33-14-19(15-33)8-28(36)37/h2-5,18-25H,6-17H2,1H3,(H,36,37)/t18-,20+,21+,22-,23-,24-,25+,31?/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 264 -37.5n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220394
PNG
(US9290488, CC04)
Show SMILES CC12C[C@@H]3C[C@H]1C[C@H]2C[C@@H](C3)N1[C@H]2COC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CCC[C@H]2C(O)=O)c1=O |r,THB:9:11:18.19.17:13.15.14|
Show InChI InChI=1S/C31H40N4O4/c1-31-15-18-9-19(31)11-20(31)12-21(10-18)34-23-13-22(14-24(34)17-39-16-23)35-26-6-3-2-5-25(26)32-28(29(35)36)33-8-4-7-27(33)30(37)38/h2-3,5-6,18-24,27H,4,7-17H2,1H3,(H,37,38)/t18-,19+,20+,21-,22-,23-,24+,27+,31?/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 272 -37.5n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220372
PNG
(US9290488, E53a(ii))
Show SMILES CC1(C)[C@@H]2C[C@H]1[C@H](CCN1[C@H]3CCC[C@@H]1C[C@@H](C3)n1c3ccccc3nc(N3CC[C@H]3C(O)=O)c1=O)CC2 |r,THB:8:9:16.17.15:11.13.12|
Show InChI InChI=1S/C31H42N4O3/c1-31(2)20-11-10-19(24(31)16-20)12-14-33-21-6-5-7-22(33)18-23(17-21)35-26-9-4-3-8-25(26)32-28(29(35)36)34-15-13-27(34)30(37)38/h3-4,8-9,19-24,27H,5-7,10-18H2,1-2H3,(H,37,38)/t19-,20-,21-,22+,23+,24-,27-/m0/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 274 -37.5n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 μg membrane protein (recombinant kappa opioid rece...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220359
PNG
(US9290488, B2a(ii))
Show SMILES OC(=O)[C@@H]1CCN1c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@@H]2C[C@H]3CCC[C@H](C3)C2)c1=O |r,THB:25:24:16.17.23:19.21.20|
Show InChI InChI=1S/C29H38N4O3/c34-28-27(31-12-11-26(31)29(35)36)30-24-9-1-2-10-25(24)33(28)23-16-20-7-4-8-21(17-23)32(20)22-14-18-5-3-6-19(13-18)15-22/h1-2,9-10,18-23,26H,3-8,11-17H2,(H,35,36)/t18-,19+,20-,21+,22+,23+,26-/m0/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 289 -37.3n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 μg membrane protein (recombinant kappa opioid rece...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220367
PNG
(US9290488, C2a(ii))
Show SMILES OC(=O)[C@@H]1CCN1c1nc2ccccc2n([C@@H]2C[C@@H]3COC[C@H](C2)N3[C@@H]2C[C@H]3CCC[C@H](C3)C2)c1=O |r,THB:25:24:16.17.23:19.21.20|
Show InChI InChI=1S/C28H36N4O4/c33-27-26(30-9-8-25(30)28(34)35)29-23-6-1-2-7-24(23)32(27)20-13-21-15-36-16-22(14-20)31(21)19-11-17-4-3-5-18(10-17)12-19/h1-2,6-7,17-22,25H,3-5,8-16H2,(H,34,35)/t17-,18+,19+,20-,21-,22+,25-/m0/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 294 -37.3n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220356
PNG
(US9290488, A11a(i))
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@@H]2C(O)=O)c1=O |r,THB:8:10:16.17.15:12.13|
Show InChI InChI=1S/C29H38N4O3/c1-17-10-18-12-19(11-17)14-22(13-18)32-20-6-7-21(32)16-23(15-20)33-25-5-3-2-4-24(25)30-27(28(33)34)31-9-8-26(31)29(35)36/h2-5,17-23,26H,6-16H2,1H3,(H,35,36)/t17-,18-,19+,20-,21+,22+,23+,26-/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 323 -37.0n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 μg membrane protein (recombinant kappa opioid rece...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220369
PNG
(US9290488, C21a)
Show SMILES CC12C[C@@H]3C[C@H]1C[C@H]2C[C@@H](C3)N1[C@H]2COC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC(C2)C(O)=O)c1=O |r,THB:9:11:18.19.17:13.15.14|
Show InChI InChI=1S/C30H38N4O4/c1-30-12-17-6-19(30)8-20(30)9-21(7-17)33-23-10-22(11-24(33)16-38-15-23)34-26-5-3-2-4-25(26)31-27(28(34)35)32-13-18(14-32)29(36)37/h2-5,17-24H,6-16H2,1H3,(H,36,37)/t17-,19+,20+,21-,22-,23-,24+,30?/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 381 -36.6n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220376
PNG
(US9290488, K29b)
Show SMILES OC(=O)CC1CN(C1)c1nc2ccccc2n([C@@H]2C[C@@H]3CC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:25:24:17.18.23:20.21|
Show InChI InChI=1S/C30H40N4O3/c35-28(36)14-21-17-32(18-21)29-30(37)34(27-8-4-3-7-26(27)31-29)25-15-22-9-10-23(16-25)33(22)24-12-19-5-1-2-6-20(11-19)13-24/h3-4,7-8,19-25H,1-2,5-6,9-18H2,(H,35,36)/t19-,20+,22-,23+,24-,25+
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 494 -36.0n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220359
PNG
(US9290488, B2a(ii))
Show SMILES OC(=O)[C@@H]1CCN1c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@@H]2C[C@H]3CCC[C@H](C3)C2)c1=O |r,THB:25:24:16.17.23:19.21.20|
Show InChI InChI=1S/C29H38N4O3/c34-28-27(31-12-11-26(31)29(35)36)30-24-9-1-2-10-25(24)33(28)23-16-20-7-4-8-21(17-23)32(20)22-14-18-5-3-6-19(13-18)15-22/h1-2,9-10,18-23,26H,3-8,11-17H2,(H,35,36)/t18-,19+,20-,21+,22+,23+,26-/m0/s1
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 500 -36.0n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220356
PNG
(US9290488, A11a(i))
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@@H]2C(O)=O)c1=O |r,THB:8:10:16.17.15:12.13|
Show InChI InChI=1S/C29H38N4O3/c1-17-10-18-12-19(11-17)14-22(13-18)32-20-6-7-21(32)16-23(15-20)33-25-5-3-2-4-24(25)30-27(28(33)34)31-9-8-26(31)29(35)36/h2-5,17-23,26H,6-16H2,1H3,(H,35,36)/t17-,18-,19+,20-,21+,22+,23+,26-/m1/s1
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 502 -36.0n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220393
PNG
(US9290488, CC03)
Show SMILES OC(=O)[C@@H]1CCCN1c1nc2ccccc2n([C@@H]2C[C@@H]3COC[C@H](C2)N3[C@@H]2C[C@H]3CCC[C@H](CC3)C2)c1=O |r,THB:26:25:17.18.24:20.22.21|
Show InChI InChI=1S/C30H40N4O4/c35-29-28(32-12-4-9-27(32)30(36)37)31-25-7-1-2-8-26(25)34(29)22-15-23-17-38-18-24(16-22)33(23)21-13-19-5-3-6-20(14-21)11-10-19/h1-2,7-8,19-24,27H,3-6,9-18H2,(H,36,37)/t19-,20+,21+,22-,23-,24+,27-/m0/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 511 -35.9n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays (screening and dose-displacement) used 0.1 nM [3H]-nociceptin (NEN; 87.7 Ci/mmole) with 10-20 μg membrane protein in a ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220373
PNG
(US9290488, E54a)
Show SMILES CC1(C)[C@@H]2C[C@H]1[C@H](CCN1[C@H]3CCC[C@@H]1C[C@@H](C3)n1c3ccccc3nc(N3CC(C3)C(O)=O)c1=O)CC2 |r,THB:8:9:16.17.15:11.13.12|
Show InChI InChI=1S/C31H42N4O3/c1-31(2)21-11-10-19(25(31)14-21)12-13-34-22-6-5-7-23(34)16-24(15-22)35-27-9-4-3-8-26(27)32-28(29(35)36)33-17-20(18-33)30(37)38/h3-4,8-9,19-25H,5-7,10-18H2,1-2H3,(H,37,38)/t19-,21-,22-,23+,24+,25-/m0/s1
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 744 -35.0n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220391
PNG
(US9290488, CC01)
Show SMILES OC(=O)[C@@H]1CCCN1c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@@H]2C[C@H]3CCC[C@H](C3)C2)c1=O |r,THB:26:25:17.18.24:20.22.21|
Show InChI InChI=1S/C30H40N4O3/c35-29-28(32-13-5-12-27(32)30(36)37)31-25-10-1-2-11-26(25)34(29)24-17-21-8-4-9-22(18-24)33(21)23-15-19-6-3-7-20(14-19)16-23/h1-2,10-11,19-24,27H,3-9,12-18H2,(H,36,37)/t19-,20+,21-,22+,23+,24+,27-/m0/s1
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 919 -34.5n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Delta-type opioid receptor


(Homo sapiens (Human))		BDBM220373
PNG
(US9290488, E54a)
Show SMILES CC1(C)[C@@H]2C[C@H]1[C@H](CCN1[C@H]3CCC[C@@H]1C[C@@H](C3)n1c3ccccc3nc(N3CC(C3)C(O)=O)c1=O)CC2 |r,THB:8:9:16.17.15:11.13.12|
Show InChI InChI=1S/C31H42N4O3/c1-31(2)21-11-10-19(25(31)14-21)12-13-34-22-6-5-7-23(34)16-24(15-22)35-27-9-4-3-8-26(27)32-28(29(35)36)33-17-20(18-33)30(37)38/h3-4,8-9,19-25H,5-7,10-18H2,1-2H3,(H,37,38)/t19-,21-,22-,23+,24+,25-/m0/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 1.51E+3 -33.2n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose-displacement assays used 0.2 nM [3H]-Naltrindole (NEN; 33.0 Ci/mmole) with 10-20 μg membrane protein (recombinant delta opioid re...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Delta-type opioid receptor


(Homo sapiens (Human))		BDBM220365
PNG
(US9290488, B21a)
Show SMILES CC12C[C@@H]3C[C@H]1C[C@H]2C[C@@H](C3)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC(C2)C(O)=O)c1=O |r,THB:9:11:18.19.17:13.15.14|
Show InChI InChI=1S/C31H40N4O3/c1-31-15-18-9-20(31)11-21(31)12-24(10-18)34-22-5-4-6-23(34)14-25(13-22)35-27-8-3-2-7-26(27)32-28(29(35)36)33-16-19(17-33)30(37)38/h2-3,7-8,18-25H,4-6,9-17H2,1H3,(H,37,38)/t18-,20+,21+,22-,23+,24-,25+,31?/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 1.52E+3 -33.2n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose-displacement assays used 0.2 nM [3H]-Naltrindole (NEN; 33.0 Ci/mmole) with 10-20 μg membrane protein (recombinant delta opioid re...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220373
PNG
(US9290488, E54a)
Show SMILES CC1(C)[C@@H]2C[C@H]1[C@H](CCN1[C@H]3CCC[C@@H]1C[C@@H](C3)n1c3ccccc3nc(N3CC(C3)C(O)=O)c1=O)CC2 |r,THB:8:9:16.17.15:11.13.12|
Show InChI InChI=1S/C31H42N4O3/c1-31(2)21-11-10-19(25(31)14-21)12-13-34-22-6-5-7-23(34)16-24(15-22)35-27-9-4-3-8-26(27)32-28(29(35)36)33-17-20(18-33)30(37)38/h3-4,8-9,19-25H,5-7,10-18H2,1-2H3,(H,37,38)/t19-,21-,22-,23+,24+,25-/m0/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 1.77E+3 -32.8n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 μg membrane protein (recombinant kappa opioid rece...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Delta-type opioid receptor


(Homo sapiens (Human))		BDBM220371
PNG
(US9290488, E53a(i))
Show SMILES CC1(C)[C@@H]2C[C@H]1[C@H](CCN1[C@H]3CCC[C@@H]1C[C@@H](C3)n1c3ccccc3nc(N3CC[C@@H]3C(O)=O)c1=O)CC2 |r,THB:8:9:16.17.15:11.13.12|
Show InChI InChI=1S/C31H42N4O3/c1-31(2)20-11-10-19(24(31)16-20)12-14-33-21-6-5-7-22(33)18-23(17-21)35-26-9-4-3-8-25(26)32-28(29(35)36)34-15-13-27(34)30(37)38/h3-4,8-9,19-24,27H,5-7,10-18H2,1-2H3,(H,37,38)/t19-,20-,21-,22+,23+,24-,27+/m0/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 1.77E+3 -32.8n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose-displacement assays used 0.2 nM [3H]-Naltrindole (NEN; 33.0 Ci/mmole) with 10-20 μg membrane protein (recombinant delta opioid re...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Delta-type opioid receptor


(Homo sapiens (Human))		BDBM220362
PNG
(US9290488, B12a)
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC(C2)C(O)=O)c1=O |r,THB:8:10:17.18.16:12.14.13|
Show InChI InChI=1S/C30H40N4O3/c1-18-9-19-11-20(10-18)13-24(12-19)33-22-5-4-6-23(33)15-25(14-22)34-27-8-3-2-7-26(27)31-28(29(34)35)32-16-21(17-32)30(36)37/h2-3,7-8,18-25H,4-6,9-17H2,1H3,(H,36,37)/t18-,19-,20+,22-,23+,24+,25+
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 2.62E+3 -31.9n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose-displacement assays used 0.2 nM [3H]-Naltrindole (NEN; 33.0 Ci/mmole) with 10-20 μg membrane protein (recombinant delta opioid re...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220368
PNG
(US9290488, C20a(ii))
Show SMILES CC12C[C@@H]3C[C@H]1C[C@H]2C[C@@H](C3)N1[C@H]2COC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@H]2C(O)=O)c1=O |r,THB:9:11:18.19.17:13.15.14|
Show InChI InChI=1S/C30H38N4O4/c1-30-14-17-8-18(30)10-19(30)11-20(9-17)33-22-12-21(13-23(33)16-38-15-22)34-25-5-3-2-4-24(25)31-27(28(34)35)32-7-6-26(32)29(36)37/h2-5,17-23,26H,6-16H2,1H3,(H,36,37)/t17-,18+,19+,20-,21-,22-,23+,26+,30?/m1/s1
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 2.83E+3 -31.7n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Delta-type opioid receptor


(Homo sapiens (Human))		BDBM220356
PNG
(US9290488, A11a(i))
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@@H]2C(O)=O)c1=O |r,THB:8:10:16.17.15:12.13|
Show InChI InChI=1S/C29H38N4O3/c1-17-10-18-12-19(11-17)14-22(13-18)32-20-6-7-21(32)16-23(15-20)33-25-5-3-2-4-24(25)30-27(28(33)34)31-9-8-26(31)29(35)36/h2-5,17-23,26H,6-16H2,1H3,(H,35,36)/t17-,18-,19+,20-,21+,22+,23+,26-/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 3.05E+3 -31.5n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose-displacement assays used 0.2 nM [3H]-Naltrindole (NEN; 33.0 Ci/mmole) with 10-20 μg membrane protein (recombinant delta opioid re...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220371
PNG
(US9290488, E53a(i))
Show SMILES CC1(C)[C@@H]2C[C@H]1[C@H](CCN1[C@H]3CCC[C@@H]1C[C@@H](C3)n1c3ccccc3nc(N3CC[C@@H]3C(O)=O)c1=O)CC2 |r,THB:8:9:16.17.15:11.13.12|
Show InChI InChI=1S/C31H42N4O3/c1-31(2)20-11-10-19(24(31)16-20)12-14-33-21-6-5-7-22(33)18-23(17-21)35-26-9-4-3-8-25(26)32-28(29(35)36)34-15-13-27(34)30(37)38/h3-4,8-9,19-24,27H,5-7,10-18H2,1-2H3,(H,37,38)/t19-,20-,21-,22+,23+,24-,27+/m0/s1
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 3.42E+3 -31.2n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand binding assays were conducted using freshly thawed membranes expressing human μ-receptors (Perkin Elmer, Shelton, Conn.). Radioligand ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Delta-type opioid receptor


(Homo sapiens (Human))		BDBM220363
PNG
(US9290488, B20a(i))
Show SMILES CC12C[C@@H]3C[C@H]1C[C@H]2C[C@@H](C3)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@@H]2C(O)=O)c1=O |r,THB:9:11:18.19.17:13.15.14|
Show InChI InChI=1S/C31H40N4O3/c1-31-17-18-11-19(31)13-20(31)14-23(12-18)34-21-5-4-6-22(34)16-24(15-21)35-26-8-3-2-7-25(26)32-28(29(35)36)33-10-9-27(33)30(37)38/h2-3,7-8,18-24,27H,4-6,9-17H2,1H3,(H,37,38)/t18-,19+,20+,21-,22+,23-,24+,27-,31?/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 3.44E+3 -31.2n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose-displacement assays used 0.2 nM [3H]-Naltrindole (NEN; 33.0 Ci/mmole) with 10-20 μg membrane protein (recombinant delta opioid re...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Delta-type opioid receptor


(Homo sapiens (Human))		BDBM220364
PNG
(US9290488, B20a(ii))
Show SMILES CC12C[C@@H]3C[C@H]1C[C@H]2C[C@@H](C3)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@H]2C(O)=O)c1=O |r,THB:9:11:18.19.17:13.15.14|
Show InChI InChI=1S/C31H40N4O3/c1-31-17-18-11-19(31)13-20(31)14-23(12-18)34-21-5-4-6-22(34)16-24(15-21)35-26-8-3-2-7-25(26)32-28(29(35)36)33-10-9-27(33)30(37)38/h2-3,7-8,18-24,27H,4-6,9-17H2,1H3,(H,37,38)/t18-,19+,20+,21-,22+,23-,24+,27+,31?/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 3.92E+3 -30.9n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose-displacement assays used 0.2 nM [3H]-Naltrindole (NEN; 33.0 Ci/mmole) with 10-20 μg membrane protein (recombinant delta opioid re...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Delta-type opioid receptor


(Homo sapiens (Human))		BDBM220366
PNG
(US9290488, B34a)
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC(CC(O)=O)C2)c1=O |r,THB:8:10:17.18.16:12.14.13|
Show InChI InChI=1S/C31H42N4O3/c1-19-9-20-11-21(10-19)13-25(12-20)34-23-5-4-6-24(34)16-26(15-23)35-28-8-3-2-7-27(28)32-30(31(35)38)33-17-22(18-33)14-29(36)37/h2-3,7-8,19-26H,4-6,9-18H2,1H3,(H,36,37)/t19-,20-,21+,23-,24+,25+,26+
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 3.99E+3 -30.8n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose-displacement assays used 0.2 nM [3H]-Naltrindole (NEN; 33.0 Ci/mmole) with 10-20 μg membrane protein (recombinant delta opioid re...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Delta-type opioid receptor


(Homo sapiens (Human))		BDBM220376
PNG
(US9290488, K29b)
Show SMILES OC(=O)CC1CN(C1)c1nc2ccccc2n([C@@H]2C[C@@H]3CC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:25:24:17.18.23:20.21|
Show InChI InChI=1S/C30H40N4O3/c35-28(36)14-21-17-32(18-21)29-30(37)34(27-8-4-3-7-26(27)31-29)25-15-22-9-10-23(16-25)33(22)24-12-19-5-1-2-6-20(11-19)13-24/h3-4,7-8,19-25H,1-2,5-6,9-18H2,(H,35,36)/t19-,20+,22-,23+,24-,25+
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 4.47E+3 -30.5n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose-displacement assays used 0.2 nM [3H]-Naltrindole (NEN; 33.0 Ci/mmole) with 10-20 μg membrane protein (recombinant delta opioid re...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Delta-type opioid receptor


(Homo sapiens (Human))		BDBM220372
PNG
(US9290488, E53a(ii))
Show SMILES CC1(C)[C@@H]2C[C@H]1[C@H](CCN1[C@H]3CCC[C@@H]1C[C@@H](C3)n1c3ccccc3nc(N3CC[C@H]3C(O)=O)c1=O)CC2 |r,THB:8:9:16.17.15:11.13.12|
Show InChI InChI=1S/C31H42N4O3/c1-31(2)20-11-10-19(24(31)16-20)12-14-33-21-6-5-7-22(33)18-23(17-21)35-26-9-4-3-8-25(26)32-28(29(35)36)34-15-13-27(34)30(37)38/h3-4,8-9,19-24,27H,5-7,10-18H2,1-2H3,(H,37,38)/t19-,20-,21-,22+,23+,24-,27-/m0/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 4.86E+3 -30.3n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose-displacement assays used 0.2 nM [3H]-Naltrindole (NEN; 33.0 Ci/mmole) with 10-20 μg membrane protein (recombinant delta opioid re...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Delta-type opioid receptor


(Homo sapiens (Human))		BDBM220377
PNG
(US9290488, L2b(i))
Show SMILES OC(=O)[C@H]1CCN1c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:25:24:16.17.23:19.21.20|
Show InChI InChI=1S/C30H40N4O3/c35-29-28(32-13-12-27(32)30(36)37)31-25-10-3-4-11-26(25)34(29)24-17-21-8-5-9-22(18-24)33(21)23-15-19-6-1-2-7-20(14-19)16-23/h3-4,10-11,19-24,27H,1-2,5-9,12-18H2,(H,36,37)/t19-,20+,21-,22+,23-,24+,27-/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 6.41E+3 -29.6n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose-displacement assays used 0.2 nM [3H]-Naltrindole (NEN; 33.0 Ci/mmole) with 10-20 μg membrane protein (recombinant delta opioid re...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220368
PNG
(US9290488, C20a(ii))
Show SMILES CC12C[C@@H]3C[C@H]1C[C@H]2C[C@@H](C3)N1[C@H]2COC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@H]2C(O)=O)c1=O |r,THB:9:11:18.19.17:13.15.14|
Show InChI InChI=1S/C30H38N4O4/c1-30-14-17-8-18(30)10-19(30)11-20(9-17)33-22-12-21(13-23(33)16-38-15-22)34-25-5-3-2-4-24(25)31-27(28(34)35)32-7-6-26(32)29(36)37/h2-5,17-23,26H,6-16H2,1H3,(H,36,37)/t17-,18+,19+,20-,21-,22-,23+,26+,30?/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 7.05E+3 -29.4n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose displacement assays used 0.4-0.8 nM [3H]-U69,593 (NEN; 40 Ci/mmole) with 10-20 μg membrane protein (recombinant kappa opioid rece...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Delta-type opioid receptor


(Homo sapiens (Human))		BDBM220368
PNG
(US9290488, C20a(ii))
Show SMILES CC12C[C@@H]3C[C@H]1C[C@H]2C[C@@H](C3)N1[C@H]2COC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@H]2C(O)=O)c1=O |r,THB:9:11:18.19.17:13.15.14|
Show InChI InChI=1S/C30H38N4O4/c1-30-14-17-8-18(30)10-19(30)11-20(9-17)33-22-12-21(13-23(33)16-38-15-22)34-25-5-3-2-4-24(25)31-27(28(34)35)32-7-6-26(32)29(36)37/h2-5,17-23,26H,6-16H2,1H3,(H,36,37)/t17-,18+,19+,20-,21-,22-,23+,26+,30?/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 7.67E+3 -29.2n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose-displacement assays used 0.2 nM [3H]-Naltrindole (NEN; 33.0 Ci/mmole) with 10-20 μg membrane protein (recombinant delta opioid re...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Delta-type opioid receptor


(Homo sapiens (Human))		BDBM220361
PNG
(US9290488, B11a(ii))
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@H]2C(O)=O)c1=O |r,THB:8:10:17.18.16:12.14.13|
Show InChI InChI=1S/C30H40N4O3/c1-18-11-19-13-20(12-18)15-23(14-19)33-21-5-4-6-22(33)17-24(16-21)34-26-8-3-2-7-25(26)31-28(29(34)35)32-10-9-27(32)30(36)37/h2-3,7-8,18-24,27H,4-6,9-17H2,1H3,(H,36,37)/t18-,19-,20+,21-,22+,23+,24+,27-/m0/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 8.00E+3 -29.1n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose-displacement assays used 0.2 nM [3H]-Naltrindole (NEN; 33.0 Ci/mmole) with 10-20 μg membrane protein (recombinant delta opioid re...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Delta-type opioid receptor


(Homo sapiens (Human))		BDBM220357
PNG
(US9290488, A11a(ii))
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@H]2C(O)=O)c1=O |r,THB:8:10:16.17.15:12.13|
Show InChI InChI=1S/C29H38N4O3/c1-17-10-18-12-19(11-17)14-22(13-18)32-20-6-7-21(32)16-23(15-20)33-25-5-3-2-4-24(25)30-27(28(33)34)31-9-8-26(31)29(35)36/h2-5,17-23,26H,6-16H2,1H3,(H,35,36)/t17-,18-,19+,20-,21+,22+,23+,26-/m0/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 1.15E+4 -28.2n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose-displacement assays used 0.2 nM [3H]-Naltrindole (NEN; 33.0 Ci/mmole) with 10-20 μg membrane protein (recombinant delta opioid re...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Delta-type opioid receptor


(Homo sapiens (Human))		BDBM220378
PNG
(US9290488, L2b(ii))
Show SMILES OC(=O)[C@@H]1CCN1c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:25:24:16.17.23:19.21.20|
Show InChI InChI=1S/C30H40N4O3/c35-29-28(32-13-12-27(32)30(36)37)31-25-10-3-4-11-26(25)34(29)24-17-21-8-5-9-22(18-24)33(21)23-15-19-6-1-2-7-20(14-19)16-23/h3-4,10-11,19-24,27H,1-2,5-9,12-18H2,(H,36,37)/t19-,20+,21-,22+,23-,24+,27-/m0/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 1.25E+4 -28.0n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose-displacement assays used 0.2 nM [3H]-Naltrindole (NEN; 33.0 Ci/mmole) with 10-20 μg membrane protein (recombinant delta opioid re...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Delta-type opioid receptor


(Homo sapiens (Human))		BDBM220375
PNG
(US9290488, K2b(ii))
Show SMILES OC(=O)[C@@H]1CCN1c1nc2ccccc2n([C@@H]2C[C@@H]3CC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:24:23:16.17.22:19.20|
Show InChI InChI=1S/C29H38N4O3/c34-28-27(31-12-11-26(31)29(35)36)30-24-7-3-4-8-25(24)33(28)23-16-20-9-10-21(17-23)32(20)22-14-18-5-1-2-6-19(13-18)15-22/h3-4,7-8,18-23,26H,1-2,5-6,9-17H2,(H,35,36)/t18-,19+,20-,21+,22-,23+,26-/m0/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
 1.54E+4 -27.5n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose-displacement assays used 0.2 nM [3H]-Naltrindole (NEN; 33.0 Ci/mmole) with 10-20 μg membrane protein (recombinant delta opioid re...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Delta-type opioid receptor


(Homo sapiens (Human))		BDBM220359
PNG
(US9290488, B2a(ii))
Show SMILES OC(=O)[C@@H]1CCN1c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@@H]2C[C@H]3CCC[C@H](C3)C2)c1=O |r,THB:25:24:16.17.23:19.21.20|
Show InChI InChI=1S/C29H38N4O3/c34-28-27(31-12-11-26(31)29(35)36)30-24-9-1-2-10-25(24)33(28)23-16-20-7-4-8-21(17-23)32(20)22-14-18-5-3-6-19(13-18)15-22/h1-2,9-10,18-23,26H,3-8,11-17H2,(H,35,36)/t18-,19+,20-,21+,22+,23+,26-/m0/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
>2.00E+4>-26.8n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose-displacement assays used 0.2 nM [3H]-Naltrindole (NEN; 33.0 Ci/mmole) with 10-20 μg membrane protein (recombinant delta opioid re...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Delta-type opioid receptor


(Homo sapiens (Human))		BDBM220384
PNG
(US9290488, ZA05)
Show SMILES CN(C)[C@@H]1CN([C@@H]1C(O)=O)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:28:27:19.20.26:22.24.23|
Show InChI InChI=1S/C32H45N5O3/c1-34(2)28-19-35(29(28)32(39)40)30-31(38)37(27-13-6-5-12-26(27)33-30)25-17-22-10-7-11-23(18-25)36(22)24-15-20-8-3-4-9-21(14-20)16-24/h5-6,12-13,20-25,28-29H,3-4,7-11,14-19H2,1-2H3,(H,39,40)/t20-,21+,22-,23+,24-,25+,28-,29+/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
>2.00E+4>-26.8n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose-displacement assays used 0.2 nM [3H]-Naltrindole (NEN; 33.0 Ci/mmole) with 10-20 μg membrane protein (recombinant delta opioid re...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Delta-type opioid receptor


(Homo sapiens (Human))		BDBM220383
PNG
(US9290488, ZA04)
Show SMILES N[C@@H]1CN([C@@H]1C(O)=O)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:26:25:17.18.24:20.22.21|
Show InChI InChI=1S/C30H41N5O3/c31-24-17-33(27(24)30(37)38)28-29(36)35(26-11-4-3-10-25(26)32-28)23-15-20-8-5-9-21(16-23)34(20)22-13-18-6-1-2-7-19(12-18)14-22/h3-4,10-11,18-24,27H,1-2,5-9,12-17,31H2,(H,37,38)/t18-,19+,20-,21+,22-,23+,24-,27+/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
>2.00E+4>-26.8n/an/an/an/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Radioligand dose-displacement assays used 0.2 nM [3H]-Naltrindole (NEN; 33.0 Ci/mmole) with 10-20 μg membrane protein (recombinant delta opioid re...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220357
PNG
(US9290488, A11a(ii))
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@H]2C(O)=O)c1=O |r,THB:8:10:16.17.15:12.13|
Show InChI InChI=1S/C29H38N4O3/c1-17-10-18-12-19(11-17)14-22(13-18)32-20-6-7-21(32)16-23(15-20)33-25-5-3-2-4-24(25)30-27(28(33)34)31-9-8-26(31)29(35)36/h2-5,17-23,26H,6-16H2,1H3,(H,35,36)/t17-,18-,19+,20-,21+,22+,23+,26-/m0/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 42.5n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220373
PNG
(US9290488, E54a)
Show SMILES CC1(C)[C@@H]2C[C@H]1[C@H](CCN1[C@H]3CCC[C@@H]1C[C@@H](C3)n1c3ccccc3nc(N3CC(C3)C(O)=O)c1=O)CC2 |r,THB:8:9:16.17.15:11.13.12|
Show InChI InChI=1S/C31H42N4O3/c1-31(2)21-11-10-19(25(31)14-21)12-13-34-22-6-5-7-23(34)16-24(15-22)35-27-9-4-3-8-26(27)32-28(29(35)36)33-17-20(18-33)30(37)38/h3-4,8-9,19-25H,5-7,10-18H2,1-2H3,(H,37,38)/t19-,21-,22-,23+,24+,25-/m0/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 21.7n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220379
PNG
(US9290488, L29b)
Show SMILES OC(=O)CC1CN(C1)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:26:25:17.18.24:20.22.21|
Show InChI InChI=1S/C31H42N4O3/c36-29(37)15-22-18-33(19-22)30-31(38)35(28-11-4-3-10-27(28)32-30)26-16-23-8-5-9-24(17-26)34(23)25-13-20-6-1-2-7-21(12-20)14-25/h3-4,10-11,20-26H,1-2,5-9,12-19H2,(H,36,37)/t20-,21+,23-,24+,25-,26+
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 4.20n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220383
PNG
(US9290488, ZA04)
Show SMILES N[C@@H]1CN([C@@H]1C(O)=O)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:26:25:17.18.24:20.22.21|
Show InChI InChI=1S/C30H41N5O3/c31-24-17-33(27(24)30(37)38)28-29(36)35(26-11-4-3-10-25(26)32-28)23-15-20-8-5-9-21(16-23)34(20)22-13-18-6-1-2-7-19(12-18)14-22/h3-4,10-11,18-24,27H,1-2,5-9,12-17,31H2,(H,37,38)/t18-,19+,20-,21+,22-,23+,24-,27+/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 5.84n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220356
PNG
(US9290488, A11a(i))
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@@H]2C(O)=O)c1=O |r,THB:8:10:16.17.15:12.13|
Show InChI InChI=1S/C29H38N4O3/c1-17-10-18-12-19(11-17)14-22(13-18)32-20-6-7-21(32)16-23(15-20)33-25-5-3-2-4-24(25)30-27(28(33)34)31-9-8-26(31)29(35)36/h2-5,17-23,26H,6-16H2,1H3,(H,35,36)/t17-,18-,19+,20-,21+,22+,23+,26-/m1/s1
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 357n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220364
PNG
(US9290488, B20a(ii))
Show SMILES CC12C[C@@H]3C[C@H]1C[C@H]2C[C@@H](C3)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@H]2C(O)=O)c1=O |r,THB:9:11:18.19.17:13.15.14|
Show InChI InChI=1S/C31H40N4O3/c1-31-17-18-11-19(31)13-20(31)14-23(12-18)34-21-5-4-6-22(34)16-24(15-21)35-26-8-3-2-7-25(26)32-28(29(35)36)33-10-9-27(33)30(37)38/h2-3,7-8,18-24,27H,4-6,9-17H2,1H3,(H,37,38)/t18-,19+,20+,21-,22+,23-,24+,27+,31?/m1/s1
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 363n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220360
PNG
(US9290488, B11a(i))
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@@H]2C(O)=O)c1=O |r,THB:8:10:17.18.16:12.14.13|
Show InChI InChI=1S/C30H40N4O3/c1-18-11-19-13-20(12-18)15-23(14-19)33-21-5-4-6-22(33)17-24(16-21)34-26-8-3-2-7-25(26)31-28(29(34)35)32-10-9-27(32)30(36)37/h2-3,7-8,18-24,27H,4-6,9-17H2,1H3,(H,36,37)/t18-,19-,20+,21-,22+,23+,24+,27-/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 16.2n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220364
PNG
(US9290488, B20a(ii))
Show SMILES CC12C[C@@H]3C[C@H]1C[C@H]2C[C@@H](C3)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@H]2C(O)=O)c1=O |r,THB:9:11:18.19.17:13.15.14|
Show InChI InChI=1S/C31H40N4O3/c1-31-17-18-11-19(31)13-20(31)14-23(12-18)34-21-5-4-6-22(34)16-24(15-21)35-26-8-3-2-7-25(26)32-28(29(35)36)33-10-9-27(33)30(37)38/h2-3,7-8,18-24,27H,4-6,9-17H2,1H3,(H,37,38)/t18-,19+,20+,21-,22+,23-,24+,27+,31?/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 51.1n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220371
PNG
(US9290488, E53a(i))
Show SMILES CC1(C)[C@@H]2C[C@H]1[C@H](CCN1[C@H]3CCC[C@@H]1C[C@@H](C3)n1c3ccccc3nc(N3CC[C@@H]3C(O)=O)c1=O)CC2 |r,THB:8:9:16.17.15:11.13.12|
Show InChI InChI=1S/C31H42N4O3/c1-31(2)20-11-10-19(24(31)16-20)12-14-33-21-6-5-7-22(33)18-23(17-21)35-26-9-4-3-8-25(26)32-28(29(35)36)34-15-13-27(34)30(37)38/h3-4,8-9,19-24,27H,5-7,10-18H2,1-2H3,(H,37,38)/t19-,20-,21-,22+,23+,24-,27+/m0/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 65.7n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220381
PNG
(US9290488, ZA02)
Show SMILES CC(=O)N[C@@H]1CN([C@@H]1C(O)=O)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:29:28:20.21.27:23.25.24|
Show InChI InChI=1S/C32H43N5O4/c1-19(38)33-27-18-35(29(27)32(40)41)30-31(39)37(28-12-5-4-11-26(28)34-30)25-16-22-9-6-10-23(17-25)36(22)24-14-20-7-2-3-8-21(13-20)15-24/h4-5,11-12,20-25,27,29H,2-3,6-10,13-18H2,1H3,(H,33,38)(H,40,41)/t20-,21+,22-,23+,24-,25+,27-,29+/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 24.2n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220388
PNG
(US9290488, ZA09)
Show SMILES N[C@@H]1CN([C@@H]1C(O)=O)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@@H]2C[C@H]3CCC[C@H](C3)C2)c1=O |r,THB:26:25:17.18.24:20.22.21|
Show InChI InChI=1S/C29H39N5O3/c30-23-16-32(26(23)29(36)37)27-28(35)34(25-10-2-1-9-24(25)31-27)22-14-19-7-4-8-20(15-22)33(19)21-12-17-5-3-6-18(11-17)13-21/h1-2,9-10,17-23,26H,3-8,11-16,30H2,(H,36,37)/t17-,18+,19-,20+,21+,22+,23-,26+/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a>2.00E+4n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220378
PNG
(US9290488, L2b(ii))
Show SMILES OC(=O)[C@@H]1CCN1c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:25:24:16.17.23:19.21.20|
Show InChI InChI=1S/C30H40N4O3/c35-29-28(32-13-12-27(32)30(36)37)31-25-10-3-4-11-26(25)34(29)24-17-21-8-5-9-22(18-24)33(21)23-15-19-6-1-2-7-20(14-19)16-23/h3-4,10-11,19-24,27H,1-2,5-9,12-18H2,(H,36,37)/t19-,20+,21-,22+,23-,24+,27-/m0/s1
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a>2.00E+4n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220357
PNG
(US9290488, A11a(ii))
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@H]2C(O)=O)c1=O |r,THB:8:10:16.17.15:12.13|
Show InChI InChI=1S/C29H38N4O3/c1-17-10-18-12-19(11-17)14-22(13-18)32-20-6-7-21(32)16-23(15-20)33-25-5-3-2-4-24(25)30-27(28(33)34)31-9-8-26(31)29(35)36/h2-5,17-23,26H,6-16H2,1H3,(H,35,36)/t17-,18-,19+,20-,21+,22+,23+,26-/m0/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a>2.00E+4n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Kappa opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 μg/μL kappa membrane protein (in-hous...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220384
PNG
(US9290488, ZA05)
Show SMILES CN(C)[C@@H]1CN([C@@H]1C(O)=O)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:28:27:19.20.26:22.24.23|
Show InChI InChI=1S/C32H45N5O3/c1-34(2)28-19-35(29(28)32(39)40)30-31(38)37(27-13-6-5-12-26(27)33-30)25-17-22-10-7-11-23(18-25)36(22)24-15-20-8-3-4-9-21(14-20)16-24/h5-6,12-13,20-25,28-29H,3-4,7-11,14-19H2,1-2H3,(H,39,40)/t20-,21+,22-,23+,24-,25+,28-,29+/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a>2.00E+4n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Kappa opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 μg/μL kappa membrane protein (in-hous...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220372
PNG
(US9290488, E53a(ii))
Show SMILES CC1(C)[C@@H]2C[C@H]1[C@H](CCN1[C@H]3CCC[C@@H]1C[C@@H](C3)n1c3ccccc3nc(N3CC[C@H]3C(O)=O)c1=O)CC2 |r,THB:8:9:16.17.15:11.13.12|
Show InChI InChI=1S/C31H42N4O3/c1-31(2)20-11-10-19(24(31)16-20)12-14-33-21-6-5-7-22(33)18-23(17-21)35-26-9-4-3-8-25(26)32-28(29(35)36)34-15-13-27(34)30(37)38/h3-4,8-9,19-24,27H,5-7,10-18H2,1-2H3,(H,37,38)/t19-,20-,21-,22+,23+,24-,27-/m0/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 130n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220374
PNG
(US9290488, H3a)
Show SMILES OC(=O)C1CN(C1)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3C2CCCCCCCCC2)c1=O |r,THB:25:24:16.17.23:19.21.20|
Show InChI InChI=1S/C30H42N4O3/c35-29-28(32-19-21(20-32)30(36)37)31-26-15-8-9-16-27(26)34(29)25-17-23-13-10-14-24(18-25)33(23)22-11-6-4-2-1-3-5-7-12-22/h8-9,15-16,21-25H,1-7,10-14,17-20H2,(H,36,37)/t23-,24+,25+
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 40.1n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220376
PNG
(US9290488, K29b)
Show SMILES OC(=O)CC1CN(C1)c1nc2ccccc2n([C@@H]2C[C@@H]3CC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:25:24:17.18.23:20.21|
Show InChI InChI=1S/C30H40N4O3/c35-28(36)14-21-17-32(18-21)29-30(37)34(27-8-4-3-7-26(27)31-29)25-15-22-9-10-23(16-25)33(22)24-12-19-5-1-2-6-20(11-19)13-24/h3-4,7-8,19-25H,1-2,5-6,9-18H2,(H,35,36)/t19-,20+,22-,23+,24-,25+
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 7.24n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220377
PNG
(US9290488, L2b(i))
Show SMILES OC(=O)[C@H]1CCN1c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:25:24:16.17.23:19.21.20|
Show InChI InChI=1S/C30H40N4O3/c35-29-28(32-13-12-27(32)30(36)37)31-25-10-3-4-11-26(25)34(29)24-17-21-8-5-9-22(18-24)33(21)23-15-19-6-1-2-7-20(14-19)16-23/h3-4,10-11,19-24,27H,1-2,5-9,12-18H2,(H,36,37)/t19-,20+,21-,22+,23-,24+,27-/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 14.6n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220373
PNG
(US9290488, E54a)
Show SMILES CC1(C)[C@@H]2C[C@H]1[C@H](CCN1[C@H]3CCC[C@@H]1C[C@@H](C3)n1c3ccccc3nc(N3CC(C3)C(O)=O)c1=O)CC2 |r,THB:8:9:16.17.15:11.13.12|
Show InChI InChI=1S/C31H42N4O3/c1-31(2)21-11-10-19(25(31)14-21)12-13-34-22-6-5-7-23(34)16-24(15-22)35-27-9-4-3-8-26(27)32-28(29(35)36)33-17-20(18-33)30(37)38/h3-4,8-9,19-25H,5-7,10-18H2,1-2H3,(H,37,38)/t19-,21-,22-,23+,24+,25-/m0/s1
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 560n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220376
PNG
(US9290488, K29b)
Show SMILES OC(=O)CC1CN(C1)c1nc2ccccc2n([C@@H]2C[C@@H]3CC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:25:24:17.18.23:20.21|
Show InChI InChI=1S/C30H40N4O3/c35-28(36)14-21-17-32(18-21)29-30(37)34(27-8-4-3-7-26(27)31-29)25-15-22-9-10-23(16-25)33(22)24-12-19-5-1-2-6-20(11-19)13-24/h3-4,7-8,19-25H,1-2,5-6,9-18H2,(H,35,36)/t19-,20+,22-,23+,24-,25+
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a>2.00E+4n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220363
PNG
(US9290488, B20a(i))
Show SMILES CC12C[C@@H]3C[C@H]1C[C@H]2C[C@@H](C3)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@@H]2C(O)=O)c1=O |r,THB:9:11:18.19.17:13.15.14|
Show InChI InChI=1S/C31H40N4O3/c1-31-17-18-11-19(31)13-20(31)14-23(12-18)34-21-5-4-6-22(34)16-24(15-21)35-26-8-3-2-7-25(26)32-28(29(35)36)33-10-9-27(33)30(37)38/h2-3,7-8,18-24,27H,4-6,9-17H2,1H3,(H,37,38)/t18-,19+,20+,21-,22+,23-,24+,27-,31?/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a>2.00E+4n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Kappa opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 μg/μL kappa membrane protein (in-hous...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220372
PNG
(US9290488, E53a(ii))
Show SMILES CC1(C)[C@@H]2C[C@H]1[C@H](CCN1[C@H]3CCC[C@@H]1C[C@@H](C3)n1c3ccccc3nc(N3CC[C@H]3C(O)=O)c1=O)CC2 |r,THB:8:9:16.17.15:11.13.12|
Show InChI InChI=1S/C31H42N4O3/c1-31(2)20-11-10-19(24(31)16-20)12-14-33-21-6-5-7-22(33)18-23(17-21)35-26-9-4-3-8-25(26)32-28(29(35)36)34-15-13-27(34)30(37)38/h3-4,8-9,19-24,27H,5-7,10-18H2,1-2H3,(H,37,38)/t19-,20-,21-,22+,23+,24-,27-/m0/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a>2.00E+4n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Kappa opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 μg/μL kappa membrane protein (in-hous...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220375
PNG
(US9290488, K2b(ii))
Show SMILES OC(=O)[C@@H]1CCN1c1nc2ccccc2n([C@@H]2C[C@@H]3CC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:24:23:16.17.22:19.20|
Show InChI InChI=1S/C29H38N4O3/c34-28-27(31-12-11-26(31)29(35)36)30-24-7-3-4-8-25(24)33(28)23-16-20-9-10-21(17-23)32(20)22-14-18-5-1-2-6-19(13-18)15-22/h3-4,7-8,18-23,26H,1-2,5-6,9-17H2,(H,35,36)/t18-,19+,20-,21+,22-,23+,26-/m0/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a>2.00E+4n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Kappa opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 μg/μL kappa membrane protein (in-hous...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220359
PNG
(US9290488, B2a(ii))
Show SMILES OC(=O)[C@@H]1CCN1c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@@H]2C[C@H]3CCC[C@H](C3)C2)c1=O |r,THB:25:24:16.17.23:19.21.20|
Show InChI InChI=1S/C29H38N4O3/c34-28-27(31-12-11-26(31)29(35)36)30-24-9-1-2-10-25(24)33(28)23-16-20-7-4-8-21(17-23)32(20)22-14-18-5-3-6-19(13-18)15-22/h1-2,9-10,18-23,26H,3-8,11-17H2,(H,35,36)/t18-,19+,20-,21+,22+,23+,26-/m0/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 61.3n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220361
PNG
(US9290488, B11a(ii))
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@H]2C(O)=O)c1=O |r,THB:8:10:17.18.16:12.14.13|
Show InChI InChI=1S/C30H40N4O3/c1-18-11-19-13-20(12-18)15-23(14-19)33-21-5-4-6-22(33)17-24(16-21)34-26-8-3-2-7-25(26)31-28(29(34)35)32-10-9-27(32)30(36)37/h2-3,7-8,18-24,27H,4-6,9-17H2,1H3,(H,36,37)/t18-,19-,20+,21-,22+,23+,24+,27-/m0/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 6.54n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220368
PNG
(US9290488, C20a(ii))
Show SMILES CC12C[C@@H]3C[C@H]1C[C@H]2C[C@@H](C3)N1[C@H]2COC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@H]2C(O)=O)c1=O |r,THB:9:11:18.19.17:13.15.14|
Show InChI InChI=1S/C30H38N4O4/c1-30-14-17-8-18(30)10-19(30)11-20(9-17)33-22-12-21(13-23(33)16-38-15-22)34-25-5-3-2-4-24(25)31-27(28(34)35)32-7-6-26(32)29(36)37/h2-5,17-23,26H,6-16H2,1H3,(H,36,37)/t17-,18+,19+,20-,21-,22-,23+,26+,30?/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 146n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220375
PNG
(US9290488, K2b(ii))
Show SMILES OC(=O)[C@@H]1CCN1c1nc2ccccc2n([C@@H]2C[C@@H]3CC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:24:23:16.17.22:19.20|
Show InChI InChI=1S/C29H38N4O3/c34-28-27(31-12-11-26(31)29(35)36)30-24-7-3-4-8-25(24)33(28)23-16-20-9-10-21(17-23)32(20)22-14-18-5-1-2-6-19(13-18)15-22/h3-4,7-8,18-23,26H,1-2,5-6,9-17H2,(H,35,36)/t18-,19+,20-,21+,22-,23+,26-/m0/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 14.3n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220382
PNG
(US9290488, ZA03)
Show SMILES CN(C)C1(CN(C1)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O)C(O)=O |r,THB:25:24:16.17.23:19.21.20|
Show InChI InChI=1S/C32H45N5O3/c1-34(2)32(31(39)40)19-35(20-32)29-30(38)37(28-13-6-5-12-27(28)33-29)26-17-23-10-7-11-24(18-26)36(23)25-15-21-8-3-4-9-22(14-21)16-25/h5-6,12-13,21-26H,3-4,7-11,14-20H2,1-2H3,(H,39,40)/t21-,22+,23-,24+,25-,26+
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a>2.00E+4n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220385
PNG
(US9290488, ZA06)
Show SMILES CN[C@@H]1CN([C@@H]1C(O)=O)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:27:26:18.19.25:21.23.22|
Show InChI InChI=1S/C31H43N5O3/c1-32-26-18-34(28(26)31(38)39)29-30(37)36(27-12-5-4-11-25(27)33-29)24-16-21-9-6-10-22(17-24)35(21)23-14-19-7-2-3-8-20(13-19)15-23/h4-5,11-12,19-24,26,28,32H,2-3,6-10,13-18H2,1H3,(H,38,39)/t19-,20+,21-,22+,23-,24+,26-,28+/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a>2.00E+4n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220390
PNG
(US9290488, ZA11)
Show SMILES CC(=O)N[C@@H]1CN([C@@H]1C(O)=O)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@@H]2C[C@H]3CCC[C@H](C3)C2)c1=O |r,THB:29:28:20.21.27:23.25.24|
Show InChI InChI=1S/C31H41N5O4/c1-18(37)32-26-17-34(28(26)31(39)40)29-30(38)36(27-11-3-2-10-25(27)33-29)24-15-21-8-5-9-22(16-24)35(21)23-13-19-6-4-7-20(12-19)14-23/h2-3,10-11,19-24,26,28H,4-9,12-17H2,1H3,(H,32,37)(H,39,40)/t19-,20+,21-,22+,23+,24+,26-,28+/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a>2.00E+4n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220362
PNG
(US9290488, B12a)
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC(C2)C(O)=O)c1=O |r,THB:8:10:17.18.16:12.14.13|
Show InChI InChI=1S/C30H40N4O3/c1-18-9-19-11-20(10-18)13-24(12-19)33-22-5-4-6-23(33)15-25(14-22)34-27-8-3-2-7-26(27)31-28(29(34)35)32-16-21(17-32)30(36)37/h2-3,7-8,18-25H,4-6,9-17H2,1H3,(H,36,37)/t18-,19-,20+,22-,23+,24+,25+
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a>2.00E+4n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220366
PNG
(US9290488, B34a)
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC(CC(O)=O)C2)c1=O |r,THB:8:10:17.18.16:12.14.13|
Show InChI InChI=1S/C31H42N4O3/c1-19-9-20-11-21(10-19)13-25(12-20)34-23-5-4-6-24(34)16-26(15-23)35-28-8-3-2-7-27(28)32-30(31(35)38)33-17-22(18-33)14-29(36)37/h2-3,7-8,19-26H,4-6,9-18H2,1H3,(H,36,37)/t19-,20-,21+,23-,24+,25+,26+
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a>2.00E+4n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220375
PNG
(US9290488, K2b(ii))
Show SMILES OC(=O)[C@@H]1CCN1c1nc2ccccc2n([C@@H]2C[C@@H]3CC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:24:23:16.17.22:19.20|
Show InChI InChI=1S/C29H38N4O3/c34-28-27(31-12-11-26(31)29(35)36)30-24-7-3-4-8-25(24)33(28)23-16-20-9-10-21(17-23)32(20)22-14-18-5-1-2-6-19(13-18)15-22/h3-4,7-8,18-23,26H,1-2,5-6,9-17H2,(H,35,36)/t18-,19+,20-,21+,22-,23+,26-/m0/s1
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 340n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220366
PNG
(US9290488, B34a)
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC(CC(O)=O)C2)c1=O |r,THB:8:10:17.18.16:12.14.13|
Show InChI InChI=1S/C31H42N4O3/c1-19-9-20-11-21(10-19)13-25(12-20)34-23-5-4-6-24(34)16-26(15-23)35-28-8-3-2-7-27(28)32-30(31(35)38)33-17-22(18-33)14-29(36)37/h2-3,7-8,19-26H,4-6,9-18H2,1H3,(H,36,37)/t19-,20-,21+,23-,24+,25+,26+
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a>2.00E+4n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Kappa opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 μg/μL kappa membrane protein (in-hous...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220358
PNG
(US9290488, B2a(i))
Show SMILES OC(=O)[C@H]1CCN1c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@@H]2C[C@H]3CCC[C@H](C3)C2)c1=O |r,THB:25:24:16.17.23:19.21.20|
Show InChI InChI=1S/C29H38N4O3/c34-28-27(31-12-11-26(31)29(35)36)30-24-9-1-2-10-25(24)33(28)23-16-20-7-4-8-21(17-23)32(20)22-14-18-5-3-6-19(13-18)15-22/h1-2,9-10,18-23,26H,3-8,11-17H2,(H,35,36)/t18-,19+,20-,21+,22+,23+,26-/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 319n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220366
PNG
(US9290488, B34a)
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC(CC(O)=O)C2)c1=O |r,THB:8:10:17.18.16:12.14.13|
Show InChI InChI=1S/C31H42N4O3/c1-19-9-20-11-21(10-19)13-25(12-20)34-23-5-4-6-24(34)16-26(15-23)35-28-8-3-2-7-27(28)32-30(31(35)38)33-17-22(18-33)14-29(36)37/h2-3,7-8,19-26H,4-6,9-18H2,1H3,(H,36,37)/t19-,20-,21+,23-,24+,25+,26+
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 1.24n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220384
PNG
(US9290488, ZA05)
Show SMILES CN(C)[C@@H]1CN([C@@H]1C(O)=O)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:28:27:19.20.26:22.24.23|
Show InChI InChI=1S/C32H45N5O3/c1-34(2)28-19-35(29(28)32(39)40)30-31(38)37(27-13-6-5-12-26(27)33-30)25-17-22-10-7-11-23(18-25)36(22)24-15-20-8-3-4-9-21(14-20)16-24/h5-6,12-13,20-25,28-29H,3-4,7-11,14-19H2,1-2H3,(H,39,40)/t20-,21+,22-,23+,24-,25+,28-,29+/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 24.5n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220386
PNG
(US9290488, ZA07)
Show SMILES CO[C@H]1CN([C@@H]1C(O)=O)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:27:26:18.19.25:21.23.22|
Show InChI InChI=1S/C31H42N4O4/c1-39-27-18-33(28(27)31(37)38)29-30(36)35(26-12-5-4-11-25(26)32-29)24-16-21-9-6-10-22(17-24)34(21)23-14-19-7-2-3-8-20(13-19)15-23/h4-5,11-12,19-24,27-28H,2-3,6-10,13-18H2,1H3,(H,37,38)/t19-,20+,21-,22+,23-,24+,27-,28-/m0/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 22.9n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220387
PNG
(US9290488, ZA08)
Show SMILES CO[C@H]1CN([C@@H]1C(O)=O)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@@H]2C[C@H]3CCC[C@H](C3)C2)c1=O |r,THB:27:26:18.19.25:21.23.22|
Show InChI InChI=1S/C30H40N4O4/c1-38-26-17-32(27(26)30(36)37)28-29(35)34(25-11-3-2-10-24(25)31-28)23-15-20-8-5-9-21(16-23)33(20)22-13-18-6-4-7-19(12-18)14-22/h2-3,10-11,18-23,26-27H,4-9,12-17H2,1H3,(H,36,37)/t18-,19+,20-,21+,22+,23+,26-,27-/m0/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 29.3n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220356
PNG
(US9290488, A11a(i))
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@@H]2C(O)=O)c1=O |r,THB:8:10:16.17.15:12.13|
Show InChI InChI=1S/C29H38N4O3/c1-17-10-18-12-19(11-17)14-22(13-18)32-20-6-7-21(32)16-23(15-20)33-25-5-3-2-4-24(25)30-27(28(33)34)31-9-8-26(31)29(35)36/h2-5,17-23,26H,6-16H2,1H3,(H,35,36)/t17-,18-,19+,20-,21+,22+,23+,26-/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a>2.00E+4n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Kappa opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 μg/μL kappa membrane protein (in-hous...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220359
PNG
(US9290488, B2a(ii))
Show SMILES OC(=O)[C@@H]1CCN1c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@@H]2C[C@H]3CCC[C@H](C3)C2)c1=O |r,THB:25:24:16.17.23:19.21.20|
Show InChI InChI=1S/C29H38N4O3/c34-28-27(31-12-11-26(31)29(35)36)30-24-9-1-2-10-25(24)33(28)23-16-20-7-4-8-21(17-23)32(20)22-14-18-5-3-6-19(13-18)15-22/h1-2,9-10,18-23,26H,3-8,11-17H2,(H,35,36)/t18-,19+,20-,21+,22+,23+,26-/m0/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a>2.00E+4n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Kappa opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 μg/μL kappa membrane protein (in-hous...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220364
PNG
(US9290488, B20a(ii))
Show SMILES CC12C[C@@H]3C[C@H]1C[C@H]2C[C@@H](C3)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@H]2C(O)=O)c1=O |r,THB:9:11:18.19.17:13.15.14|
Show InChI InChI=1S/C31H40N4O3/c1-31-17-18-11-19(31)13-20(31)14-23(12-18)34-21-5-4-6-22(34)16-24(15-21)35-26-8-3-2-7-25(26)32-28(29(35)36)33-10-9-27(33)30(37)38/h2-3,7-8,18-24,27H,4-6,9-17H2,1H3,(H,37,38)/t18-,19+,20+,21-,22+,23-,24+,27+,31?/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a>2.00E+4n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Kappa opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 μg/μL kappa membrane protein (in-hous...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220373
PNG
(US9290488, E54a)
Show SMILES CC1(C)[C@@H]2C[C@H]1[C@H](CCN1[C@H]3CCC[C@@H]1C[C@@H](C3)n1c3ccccc3nc(N3CC(C3)C(O)=O)c1=O)CC2 |r,THB:8:9:16.17.15:11.13.12|
Show InChI InChI=1S/C31H42N4O3/c1-31(2)21-11-10-19(25(31)14-21)12-13-34-22-6-5-7-23(34)16-24(15-22)35-27-9-4-3-8-26(27)32-28(29(35)36)33-17-20(18-33)30(37)38/h3-4,8-9,19-25H,5-7,10-18H2,1-2H3,(H,37,38)/t19-,21-,22-,23+,24+,25-/m0/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a>2.00E+4n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Kappa opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 μg/μL kappa membrane protein (in-hous...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220380
PNG
(US9290488, ZA01)
Show SMILES NC1(CN(C1)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O)C(O)=O |r,THB:23:22:14.15.21:17.19.18|
Show InChI InChI=1S/C30H41N5O3/c31-30(29(37)38)17-33(18-30)27-28(36)35(26-11-4-3-10-25(26)32-27)24-15-21-8-5-9-22(16-24)34(21)23-13-19-6-1-2-7-20(12-19)14-23/h3-4,10-11,19-24H,1-2,5-9,12-18,31H2,(H,37,38)/t19-,20+,21-,22+,23-,24+
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a>2.00E+4n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220389
PNG
(US9290488, ZA10)
Show SMILES CN(C)[C@@H]1CN([C@@H]1C(O)=O)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@@H]2C[C@H]3CCC[C@H](C3)C2)c1=O |r,THB:28:27:19.20.26:22.24.23|
Show InChI InChI=1S/C31H43N5O3/c1-33(2)27-18-34(28(27)31(38)39)29-30(37)36(26-12-4-3-11-25(26)32-29)24-16-21-9-6-10-22(17-24)35(21)23-14-19-7-5-8-20(13-19)15-23/h3-4,11-12,19-24,27-28H,5-10,13-18H2,1-2H3,(H,38,39)/t19-,20+,21-,22+,23+,24+,27-,28+/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a>2.00E+4n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220359
PNG
(US9290488, B2a(ii))
Show SMILES OC(=O)[C@@H]1CCN1c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@@H]2C[C@H]3CCC[C@H](C3)C2)c1=O |r,THB:25:24:16.17.23:19.21.20|
Show InChI InChI=1S/C29H38N4O3/c34-28-27(31-12-11-26(31)29(35)36)30-24-9-1-2-10-25(24)33(28)23-16-20-7-4-8-21(17-23)32(20)22-14-18-5-3-6-19(13-18)15-22/h1-2,9-10,18-23,26H,3-8,11-17H2,(H,35,36)/t18-,19+,20-,21+,22+,23+,26-/m0/s1
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 247n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220363
PNG
(US9290488, B20a(i))
Show SMILES CC12C[C@@H]3C[C@H]1C[C@H]2C[C@@H](C3)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@@H]2C(O)=O)c1=O |r,THB:9:11:18.19.17:13.15.14|
Show InChI InChI=1S/C31H40N4O3/c1-31-17-18-11-19(31)13-20(31)14-23(12-18)34-21-5-4-6-22(34)16-24(15-21)35-26-8-3-2-7-25(26)32-28(29(35)36)33-10-9-27(33)30(37)38/h2-3,7-8,18-24,27H,4-6,9-17H2,1H3,(H,37,38)/t18-,19+,20+,21-,22+,23-,24+,27-,31?/m1/s1
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 54n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220365
PNG
(US9290488, B21a)
Show SMILES CC12C[C@@H]3C[C@H]1C[C@H]2C[C@@H](C3)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC(C2)C(O)=O)c1=O |r,THB:9:11:18.19.17:13.15.14|
Show InChI InChI=1S/C31H40N4O3/c1-31-15-18-9-20(31)11-21(31)12-24(10-18)34-22-5-4-6-23(34)14-25(13-22)35-27-8-3-2-7-26(27)32-28(29(35)36)33-16-19(17-33)30(37)38/h2-3,7-8,18-25H,4-6,9-17H2,1H3,(H,37,38)/t18-,20+,21+,22-,23+,24-,25+,31?/m1/s1
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 64n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220372
PNG
(US9290488, E53a(ii))
Show SMILES CC1(C)[C@@H]2C[C@H]1[C@H](CCN1[C@H]3CCC[C@@H]1C[C@@H](C3)n1c3ccccc3nc(N3CC[C@H]3C(O)=O)c1=O)CC2 |r,THB:8:9:16.17.15:11.13.12|
Show InChI InChI=1S/C31H42N4O3/c1-31(2)20-11-10-19(24(31)16-20)12-14-33-21-6-5-7-22(33)18-23(17-21)35-26-9-4-3-8-25(26)32-28(29(35)36)34-15-13-27(34)30(37)38/h3-4,8-9,19-24,27H,5-7,10-18H2,1-2H3,(H,37,38)/t19-,20-,21-,22+,23+,24-,27-/m0/s1
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 568n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220377
PNG
(US9290488, L2b(i))
Show SMILES OC(=O)[C@H]1CCN1c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:25:24:16.17.23:19.21.20|
Show InChI InChI=1S/C30H40N4O3/c35-29-28(32-13-12-27(32)30(36)37)31-25-10-3-4-11-26(25)34(29)24-17-21-8-5-9-22(18-24)33(21)23-15-19-6-1-2-7-20(14-19)16-23/h3-4,10-11,19-24,27H,1-2,5-9,12-18H2,(H,36,37)/t19-,20+,21-,22+,23-,24+,27-/m1/s1
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 469n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220383
PNG
(US9290488, ZA04)
Show SMILES N[C@@H]1CN([C@@H]1C(O)=O)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:26:25:17.18.24:20.22.21|
Show InChI InChI=1S/C30H41N5O3/c31-24-17-33(27(24)30(37)38)28-29(36)35(26-11-4-3-10-25(26)32-28)23-15-20-8-5-9-21(16-23)34(20)22-13-18-6-1-2-7-19(12-18)14-22/h3-4,10-11,18-24,27H,1-2,5-9,12-17,31H2,(H,37,38)/t18-,19+,20-,21+,22-,23+,24-,27+/m1/s1
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a>2.00E+4n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220371
PNG
(US9290488, E53a(i))
Show SMILES CC1(C)[C@@H]2C[C@H]1[C@H](CCN1[C@H]3CCC[C@@H]1C[C@@H](C3)n1c3ccccc3nc(N3CC[C@@H]3C(O)=O)c1=O)CC2 |r,THB:8:9:16.17.15:11.13.12|
Show InChI InChI=1S/C31H42N4O3/c1-31(2)20-11-10-19(24(31)16-20)12-14-33-21-6-5-7-22(33)18-23(17-21)35-26-9-4-3-8-25(26)32-28(29(35)36)34-15-13-27(34)30(37)38/h3-4,8-9,19-24,27H,5-7,10-18H2,1-2H3,(H,37,38)/t19-,20-,21-,22+,23+,24-,27+/m0/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a>2.00E+4n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Kappa opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 μg/μL kappa membrane protein (in-hous...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220376
PNG
(US9290488, K29b)
Show SMILES OC(=O)CC1CN(C1)c1nc2ccccc2n([C@@H]2C[C@@H]3CC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:25:24:17.18.23:20.21|
Show InChI InChI=1S/C30H40N4O3/c35-28(36)14-21-17-32(18-21)29-30(37)34(27-8-4-3-7-26(27)31-29)25-15-22-9-10-23(16-25)33(22)24-12-19-5-1-2-6-20(11-19)13-24/h3-4,7-8,19-25H,1-2,5-6,9-18H2,(H,35,36)/t19-,20+,22-,23+,24-,25+
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a>2.00E+4n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Kappa opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 μg/μL kappa membrane protein (in-hous...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220377
PNG
(US9290488, L2b(i))
Show SMILES OC(=O)[C@H]1CCN1c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:25:24:16.17.23:19.21.20|
Show InChI InChI=1S/C30H40N4O3/c35-29-28(32-13-12-27(32)30(36)37)31-25-10-3-4-11-26(25)34(29)24-17-21-8-5-9-22(18-24)33(21)23-15-19-6-1-2-7-20(14-19)16-23/h3-4,10-11,19-24,27H,1-2,5-9,12-18H2,(H,36,37)/t19-,20+,21-,22+,23-,24+,27-/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a>2.00E+4n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Kappa opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 μg/μL kappa membrane protein (in-hous...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220362
PNG
(US9290488, B12a)
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC(C2)C(O)=O)c1=O |r,THB:8:10:17.18.16:12.14.13|
Show InChI InChI=1S/C30H40N4O3/c1-18-9-19-11-20(10-18)13-24(12-19)33-22-5-4-6-23(33)15-25(14-22)34-27-8-3-2-7-26(27)31-28(29(34)35)32-16-21(17-32)30(36)37/h2-3,7-8,18-25H,4-6,9-17H2,1H3,(H,36,37)/t18-,19-,20+,22-,23+,24+,25+
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 8.14n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220365
PNG
(US9290488, B21a)
Show SMILES CC12C[C@@H]3C[C@H]1C[C@H]2C[C@@H](C3)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC(C2)C(O)=O)c1=O |r,THB:9:11:18.19.17:13.15.14|
Show InChI InChI=1S/C31H40N4O3/c1-31-15-18-9-20(31)11-21(31)12-24(10-18)34-22-5-4-6-23(34)14-25(13-22)35-27-8-3-2-7-26(27)32-28(29(35)36)33-16-19(17-33)30(37)38/h2-3,7-8,18-25H,4-6,9-17H2,1H3,(H,37,38)/t18-,20+,21+,22-,23+,24-,25+,31?/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 7.80n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220357
PNG
(US9290488, A11a(ii))
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@H]2C(O)=O)c1=O |r,THB:8:10:16.17.15:12.13|
Show InChI InChI=1S/C29H38N4O3/c1-17-10-18-12-19(11-17)14-22(13-18)32-20-6-7-21(32)16-23(15-20)33-25-5-3-2-4-24(25)30-27(28(33)34)31-9-8-26(31)29(35)36/h2-5,17-23,26H,6-16H2,1H3,(H,35,36)/t17-,18-,19+,20-,21+,22+,23+,26-/m0/s1
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 116n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220361
PNG
(US9290488, B11a(ii))
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@H]2C(O)=O)c1=O |r,THB:8:10:17.18.16:12.14.13|
Show InChI InChI=1S/C30H40N4O3/c1-18-11-19-13-20(12-18)15-23(14-19)33-21-5-4-6-22(33)17-24(16-21)34-26-8-3-2-7-25(26)31-28(29(34)35)32-10-9-27(32)30(36)37/h2-3,7-8,18-24,27H,4-6,9-17H2,1H3,(H,36,37)/t18-,19-,20+,21-,22+,23+,24+,27-/m0/s1
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a>2.00E+4n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Mu-type opioid receptor


(Homo sapiens (Human))		BDBM220384
PNG
(US9290488, ZA05)
Show SMILES CN(C)[C@@H]1CN([C@@H]1C(O)=O)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:28:27:19.20.26:22.24.23|
Show InChI InChI=1S/C32H45N5O3/c1-34(2)28-19-35(29(28)32(39)40)30-31(38)37(27-13-6-5-12-26(27)33-30)25-17-22-10-7-11-23(18-25)36(22)24-15-20-8-3-4-9-21(14-20)16-24/h5-6,12-13,20-25,28-29H,3-4,7-11,14-19H2,1-2H3,(H,39,40)/t20-,21+,22-,23+,24-,25+,28-,29+/m1/s1
PDB

NCI pathway
Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a>2.00E+4n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
[35S]GTPγS functional assays were conducted using freshly thawed membranes expressing human μ-receptors. Assay reactions were prepared by se...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220361
PNG
(US9290488, B11a(ii))
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@H]2C(O)=O)c1=O |r,THB:8:10:17.18.16:12.14.13|
Show InChI InChI=1S/C30H40N4O3/c1-18-11-19-13-20(12-18)15-23(14-19)33-21-5-4-6-22(33)17-24(16-21)34-26-8-3-2-7-25(26)31-28(29(34)35)32-10-9-27(32)30(36)37/h2-3,7-8,18-24,27H,4-6,9-17H2,1H3,(H,36,37)/t18-,19-,20+,21-,22+,23+,24+,27-/m0/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a>2.00E+4n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Kappa opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 μg/μL kappa membrane protein (in-hous...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220356
PNG
(US9290488, A11a(i))
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@@H]2C(O)=O)c1=O |r,THB:8:10:16.17.15:12.13|
Show InChI InChI=1S/C29H38N4O3/c1-17-10-18-12-19(11-17)14-22(13-18)32-20-6-7-21(32)16-23(15-20)33-25-5-3-2-4-24(25)30-27(28(33)34)31-9-8-26(31)29(35)36/h2-5,17-23,26H,6-16H2,1H3,(H,35,36)/t17-,18-,19+,20-,21+,22+,23+,26-/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 139n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220363
PNG
(US9290488, B20a(i))
Show SMILES CC12C[C@@H]3C[C@H]1C[C@H]2C[C@@H](C3)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC[C@@H]2C(O)=O)c1=O |r,THB:9:11:18.19.17:13.15.14|
Show InChI InChI=1S/C31H40N4O3/c1-31-17-18-11-19(31)13-20(31)14-23(12-18)34-21-5-4-6-22(34)16-24(15-21)35-26-8-3-2-7-25(26)32-28(29(35)36)33-10-9-27(33)30(37)38/h2-3,7-8,18-24,27H,4-6,9-17H2,1H3,(H,37,38)/t18-,19+,20+,21-,22+,23-,24+,27-,31?/m1/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 2.62n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Opioid growth factor receptor-like protein 1


(Homo sapiens (Human))		BDBM220378
PNG
(US9290488, L2b(ii))
Show SMILES OC(=O)[C@@H]1CCN1c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:25:24:16.17.23:19.21.20|
Show InChI InChI=1S/C30H40N4O3/c35-29-28(32-13-12-27(32)30(36)37)31-25-10-3-4-11-26(25)34(29)24-17-21-8-5-9-22(18-24)33(21)23-15-19-6-1-2-7-20(14-19)16-23/h3-4,10-11,19-24,27H,1-2,5-9,12-18H2,(H,36,37)/t19-,20+,21-,22+,23-,24+,27-/m0/s1
KEGG

UniProtKB/SwissProt

antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a 12n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
ORL-1 membrane solution was prepared by sequentially adding final concentrations of 0.066 μg/μL ORL-1 membrane protein, 10 μg/mL saponin, 3 ...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220362
PNG
(US9290488, B12a)
Show SMILES C[C@H]1C[C@H]2C[C@@H](C1)C[C@@H](C2)N1[C@H]2CCC[C@@H]1C[C@@H](C2)n1c2ccccc2nc(N2CC(C2)C(O)=O)c1=O |r,THB:8:10:17.18.16:12.14.13|
Show InChI InChI=1S/C30H40N4O3/c1-18-9-19-11-20(10-18)13-24(12-19)33-22-5-4-6-23(33)15-25(14-22)34-27-8-3-2-7-26(27)31-28(29(34)35)32-16-21(17-32)30(36)37/h2-3,7-8,18-25H,4-6,9-17H2,1H3,(H,36,37)/t18-,19-,20+,22-,23+,24+,25+
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a>2.00E+4n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Kappa opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 μg/μL kappa membrane protein (in-hous...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220378
PNG
(US9290488, L2b(ii))
Show SMILES OC(=O)[C@@H]1CCN1c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:25:24:16.17.23:19.21.20|
Show InChI InChI=1S/C30H40N4O3/c35-29-28(32-13-12-27(32)30(36)37)31-25-10-3-4-11-26(25)34(29)24-17-21-8-5-9-22(18-24)33(21)23-15-19-6-1-2-7-20(14-19)16-23/h3-4,10-11,19-24,27H,1-2,5-9,12-18H2,(H,36,37)/t19-,20+,21-,22+,23-,24+,27-/m0/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a>2.00E+4n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Kappa opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 μg/μL kappa membrane protein (in-hous...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
Kappa-type opioid receptor


(Homo sapiens (Human))		BDBM220383
PNG
(US9290488, ZA04)
Show SMILES N[C@@H]1CN([C@@H]1C(O)=O)c1nc2ccccc2n([C@@H]2C[C@@H]3CCC[C@H](C2)N3[C@H]2C[C@@H]3C[C@H](C2)CCCC3)c1=O |r,THB:26:25:17.18.24:20.22.21|
Show InChI InChI=1S/C30H41N5O3/c31-24-17-33(27(24)30(37)38)28-29(36)35(26-11-4-3-10-25(26)32-28)23-15-20-8-5-9-21(16-23)34(20)22-13-18-6-1-2-7-19(12-18)14-22/h3-4,10-11,18-24,27H,1-2,5-9,12-17,31H2,(H,37,38)/t18-,19+,20-,21+,22-,23+,24-,27+/m1/s1
PDB

Reactome pathway
KEGG

UniProtKB/SwissProt

B.MOAD
DrugBank
antibodypedia
GoogleScholar
AffyNet 
PC cid
PC sid
UniChem
US Patent
n/an/an/an/a>2.00E+4n/an/a7.425



Purdue Pharma L.P.

US Patent


Assay Description
Kappa opioid receptor membrane solution was prepared by sequentially adding final concentrations of 0.026 μg/μL kappa membrane protein (in-hous...

US Patent US9290488 (2016)


BindingDB Entry DOI: 10.7270/Q2GF0SCW
More data for this
Ligand-Target Pair
* indicates data uncertainty>20%